##### Table of Contents

false FY 0000065770 0000065770 2022-01-01 2022-12-31 0000065770 2021-12-31 0000065770 2022-12-31 0000065770 2021-01-01 2021-12-31 0000065770 2020-01-01 2020-12-31 0000065770 2020-12-31 0000065770 2020-10-01 2020-12-31 0000065770 2020-07-01 2020-09-30 0000065770 2020-04-01 2020-06-30 0000065770 2020-01-01 2020-03-31 0000065770 2022-10-01 2022-12-31 0000065770 2022-07-01 2022-09-30 0000065770 2022-04-01 2022-06-30 0000065770 2022-01-01 2022-03-31 0000065770 2021-10-01 2021-12-31 0000065770 2021-07-01 2021-09-30 0000065770 2021-04-01 2021-06-30 0000065770 2021-01-01 2021-03-31 0000065770 2023-01-31 0000065770 2022-06-30 0000065770 2023-02-24 0000065770 2023-02-28 0000065770 2019-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000065770 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000065770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000065770 mvis:June2021Member 2022-01-01 2022-12-31 0000065770 mvis:February2021Member 2022-01-01 2022-12-31 0000065770 mvis:December2020Member 2022-01-01 2022-12-31 0000065770 us-gaap:LicenseMember 2022-01-01 2022-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000065770 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000065770 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000065770 mvis:ProductRevenueMember 2022-01-01 2022-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember 2022-01-01 2022-12-31 0000065770 mvis:ContractRevenueMember 2022-01-01 2022-12-31 0000065770 us-gaap:ProductMember 2022-01-01 2022-12-31 0000065770 us-gaap:TechnologyServiceMember 2022-01-01 2022-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember 2022-01-01 2022-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember mvis:ConcentrationOfMajorCustomersAndSuppliersMember 2022-01-01 2022-12-31 0000065770 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000065770 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000065770 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:ShareBasedPaymentArrangementExecutiveMember 2022-01-01 2022-12-31 0000065770 srt:MinimumMember 2022-01-01 2022-12-31 0000065770 srt:MaximumMember 2022-01-01 2022-12-31 0000065770 mvis:CurrentOfficeLeaseMember 2022-01-01 2022-12-31 0000065770 mvis:NurembergOfficeLeaseMember 2022-01-01 2022-12-31 0000065770 mvis:SecondOfficeLeaseMember 2022-01-01 2022-12-31 0000065770 mvis:OfficeLeaseMember 2022-01-01 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember mvis:RSUtoRetentionandNewHireNonExecutiveMember 2022-01-01 2022-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:PSUtoExecutivesMember mvis:ShareBasedPaymentArrangementExecutiveMember 2022-01-01 2022-12-31 0000065770 mvis:PSUtoNonExecutiveMember us-gaap:PerformanceSharesMember mvis:ShareBasedPaymentArrangementNonExecutiveMember 2022-01-01 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember mvis:CEOGrantMember 2022-01-01 2022-12-31 0000065770 mvis:PSUtoNonExecutiveMember us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember mvis:RSUtoNonExecutiveMember 2022-01-01 2022-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000065770 mvis:IbeoAutomotiveSystemsGmbhMember 2022-01-01 2022-12-31 0000065770 us-gaap:SegmentContinuingOperationsMember 2021-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:OtherCurrentLiabilitiesMember 2021-12-31 0000065770 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0000065770 us-gaap:OtherLiabilitiesMember 2021-12-31 0000065770 mvis:FinancialLeaseMember 2021-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000065770 us-gaap:SegmentContinuingOperationsMember 2022-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000065770 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000065770 mvis:CorporateDebtAndUsTreasurySecuritiesMember 2022-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:ShareBasedPaymentArrangementNonExecutiveMember 2022-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2022-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000065770 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:DomesticCountryMember 2022-12-31 0000065770 us-gaap:ResearchMember 2022-12-31 0000065770 us-gaap:LicenseMember 2022-12-31 0000065770 us-gaap:OtherCurrentLiabilitiesMember 2022-12-31 0000065770 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0000065770 us-gaap:OtherLiabilitiesMember 2022-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:ShareBasedPaymentArrangementExecutiveMember 2022-12-31 0000065770 mvis:FinancialLeaseMember 2022-12-31 0000065770 mvis:NurembergOfficeLeaseMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000065770 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000065770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000065770 mvis:June2021Member 2021-01-01 2021-12-31 0000065770 us-gaap:LicenseMember 2021-01-01 2021-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0000065770 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000065770 us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0000065770 mvis:ProductRevenueMember 2021-01-01 2021-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember 2021-01-01 2021-12-31 0000065770 mvis:ContractRevenueMember 2021-01-01 2021-12-31 0000065770 us-gaap:ProductMember 2021-01-01 2021-12-31 0000065770 us-gaap:TechnologyServiceMember 2021-01-01 2021-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember 2021-01-01 2021-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember mvis:ConcentrationOfMajorCustomersAndSuppliersMember 2021-01-01 2021-12-31 0000065770 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2021-01-01 2021-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000065770 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:PSUtoNonExecutiveMember 2021-01-01 2021-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember mvis:CEOGrantMember 2021-01-01 2021-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000065770 us-gaap:SegmentContinuingOperationsMember 2020-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2020-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000065770 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000065770 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000065770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000065770 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000065770 mvis:ProductRevenueMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000065770 mvis:ContractRevenueMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000065770 us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000065770 mvis:ProductRevenueMember 2020-01-01 2020-12-31 0000065770 mvis:LicenseAndRoyaltyRevenueMember 2020-01-01 2020-12-31 0000065770 mvis:ContractRevenueMember 2020-01-01 2020-12-31 0000065770 us-gaap:ProductMember 2020-01-01 2020-12-31 0000065770 us-gaap:LicenseMember 2020-01-01 2020-12-31 0000065770 us-gaap:TechnologyServiceMember 2020-01-01 2020-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember 2020-01-01 2020-12-31 0000065770 mvis:MicrosoftConcentrationRiskMember mvis:ConcentrationOfMajorCustomersAndSuppliersMember srt:MaximumMember 2020-01-01 2020-12-31 0000065770 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2020-01-01 2020-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000065770 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000065770 us-gaap:PerformanceSharesMember mvis:PSUtoNonExecutiveMember mvis:ShareBasedPaymentArrangementNonExecutiveMember 2022-10-01 2022-12-31 0000065770 us-gaap:EmployeeStockOptionMember 2019-12-31 0000065770 us-gaap:LicenseMember 2017-04-17 0000065770 mvis:IbeoAutomotiveSystemsGmbhMember 2022-12-01 2022-12-01 0000065770 mvis:IbeoAutomotiveSystemsGmbhMember 2023-01-31 2023-01-31 0000065770 mvis:IbeoAutomotiveSystemsGmbhMember us-gaap:SubsequentEventMember 2023-01-31 2023-01-31 0000065770 mvis:NurembergOfficeLeaseMember 2022-09-01 2022-09-30 0000065770 mvis:NurembergOfficeLeaseMember 2022-09-30 0000065770 us-gaap:PerformanceSharesMember mvis:PSUtoExecutivesMember mvis:ShareBasedPaymentArrangementExecutiveMember 2022-01-01 2022-06-30 0000065770 mvis:June2021Member 2023-01-01 2023-01-31 0000065770 us-gaap:PerformanceSharesMember mvis:PSUtoNonExecutiveMember mvis:ShareBasedPaymentArrangementNonExecutiveMember 2023-01-01 2023-03-31 0000065770 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000065770 mvis:IbeoAutomotiveSystemsGmbhMember us-gaap:SubsequentEventMember 2023-04-01 2023-06-30 0000065770 us-gaap:CommonStockMember 2022-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2022-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000065770 us-gaap:RetainedEarningsMember 2022-12-31 0000065770 us-gaap:CommonStockMember 2021-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2021-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000065770 us-gaap:RetainedEarningsMember 2021-12-31 0000065770 us-gaap:CommonStockMember 2019-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2019-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000065770 us-gaap:RetainedEarningsMember 2019-12-31 0000065770 us-gaap:CommonStockMember 2020-12-31 0000065770 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000065770 us-gaap:ReceivablesFromStockholderMember 2020-12-31 0000065770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000065770 us-gaap:RetainedEarningsMember 2020-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:EUR iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-K
(Mark one)

☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to
Commission file number:
001-34170
MicroVision, Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 91-1600822
(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification Number)

18390 NE 68th Street
Redmond, Washington 98052
(Address of Principal Executive Offices, including Zip Code)
(425)
936-6847
(Registrant’s Telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol |  | Name of Each Exchange on Which Registered
Common Stock, $0.001 par value per share |  | MVIS |  | The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule
12b-2
of the Exchange Act.

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
|  |  |  | Emerging growth company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §
240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Act). Yes ☐ No ☒
The aggregate market value of common stock held by
non-affiliates
of the registrant as of June 30, 2022 was approximately $635.3 million (based upon the closing price of $3.84 per share for the registrant’s common stock as reported by the Nasdaq Global Market on that date).
The number of shares of the registrant’s common stock outstanding as of February 24, 2023 was 175,818,617.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Shareholders (the “2023 Proxy Statement”) are incorporated herein by reference in Part III of this Annual Report on Form
10-K
to the extent stated herein.

##### Table of Contents

MICROVISION, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE YEAR ENDED DECEMBER 31, 2022

Part I. |
|  | Page |
Item 1. Business |  |  | 1 |
Item 1A. Risk Factors |  |  | 6 |
Item 1B. Unresolved Staff Comments |  |  | 15 |
Item 2. Properties |  |  | 15 |
Item 3. Legal Proceedings |  |  | 15 |
Item 4. Mine Safety Disclosures |  |  | 15 |
Item 4A. Executive Officers of the Registrant |  |  | 15 |
Part II. |
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |  |  | 16 |
Item 6. Reserved |  |  | 17 |
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 17 |
Item 7A. Quantitative and Qualitative Disclosures About Market Risk |  |  | 23 |
Item 8. Financial Statements and Supplementary Data |  |  | 25 |
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |  |  | 50 |
Item 9A. Controls and Procedures |  |  | 50 |
Item 9B. Other Information |  |  | 52 |
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections |  |  | 52 |
Part III. |
Item 10. Directors, Executive Officers and Corporate Governance |  |  | 52 |
Item 11. Executive Compensation |  |  | 52 |
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |  |  | 52 |
Item 13. Certain Relationships and Related Transactions and Director Independence |  |  | 53 |
Item 14. Principal Accounting Fees and Services |  |  | 53 |
Part IV. |
Item 15. Exhibits, Financial Statement Schedules |  |  | 53 |
Item 16. Form 10-K Summary |  |  | 55 |
Signatures |  |  | 56 |

i

##### Table of Contents

PART I.

Preliminary Note Regarding Forward-Looking Statements

This Annual Report contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by those sections. Such statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and cooperative arrangements, acquisition activity and related integration efforts, technology development by third parties, future operations, financing needs or plans of MicroVision, Inc. (“we,” “our,” or “us”), as well as assumptions relating to the foregoing. The words “anticipate,” “could,” ”would,” “believe,” “estimate,” “expect,” “goal,” “may,” “plan,” “project,” “will,” and similar expressions identify forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include risk factors identified below in Item 1A.

ITEM 1. | BUSINESS

Overview

MicroVision is a global developer of lidar hardware and software solutions focused primarily on automotive lidar and advanced driver-assistance systems (ADAS) markets where we can deliver safe mobility at the speed of life. We develop a suite of light detection and ranging, or lidar, sensors and perception and validation software to the automotive market for ADAS and autonomous vehicle (AV) applications, as well as to complementary markets for non-automotive applications including industrial, robotics and smart infrastructure. Our long history of developing and commercializing the core components of our lidar hardware and related software, combined with the experience of the team we recently acquired from Ibeo Automotive Systems (Ibeo) with automotive-grade qualification, provides a potentially compelling advantage over the less-experienced recent entrants into this market.

Founded in 1993, MicroVision, Inc. is a pioneer in laser beam scanning, or LBS, technology, which is based on our patented expertise in micro-electromechanical systems, or MEMS, laser diodes, opto-mechanics, electronics, algorithms and software and how those elements are packaged into a small form factor. Throughout our history, we have combined our proprietary technology with our development expertise to create innovative solutions to address existing and emerging market needs, such as augmented reality microdisplay engines; interactive display modules; consumer lidar components; and, most recently, automotive lidar sensors and software solutions for the automotive market.

On January 31, 2023, we completed the acquisition of certain assets of Ibeo Automotive Systems GmbH, which was founded in 1998 as a lidar hardware and software provider. Ibeo developed and launched the first lidar sensor to be automotive qualified for serial production with a Tier 1 automotive supplier and that is currently available in passenger cars by premium OEMs. Ibeo developed software solutions, including perception and validation software, which are also used by premium OEMs. In addition, Ibeo sold its products for non-automotive uses such as industrial, smart infrastructure and robotics applications.

For the automotive market, our integrated solution combines our MEMS-based dynamic-range lidar sensor and perception software, to be integrated on our custom ASIC, targeted for sale to premium automotive OEMs and Tier 1 automotive suppliers. We believe that our MEMS-based lidar sensor, or MAVIN sensor, and perception software demonstrates best-in-class features and performance that exceed market expectations and outperform competitive products. Our ADAS solution is intended to leverage edge computing and custom ASICs to enable our hardware and perception software to be integrated into an OEM’s ADAS stack.

In addition to our dynamic-range and long-range MAVIN sensor and perception software solution for the automotive market, our product suite includes short- and mid-range lidar sensors, both MEMS-based and flash-based, for automotive and industrial applications, including smart infrastructure, robotics, and other commercial segments. Also, our validation software tool is used by OEMs and other customers including Tier 1s for validating vehicle sensors for ADAS and AV applications. The tool includes software that automates the manual data classification or annotation process, significantly reducing the time and resources required by OEMs to validate their ADAS and AV systems.

In the recent past, we developed micro-display concepts and designs for use in head-mounted augmented reality, or AR, headsets and developed a 1440i MEMS module supporting AR headsets. We also developed an interactive display solution targeted at the smart speakers market and a small consumer lidar sensor for use indoors with smart home systems.

1

##### Table of Contents

We completed the acquisition of Ibeo assets on January 31, 2023 pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, dated December 1, 2022, by and between our wholly owned subsidiary, MicroVision GmbH organized under the laws of The Federal Republic of Germany, and Ibeo Automotive Systems GmbH for a purchase price of EUR 15,000,000, or approximately $16.1 million, subject to potential reduction on the terms set forth in the Asset Purchase Agreement. In addition to the purchase price, pursuant to the Asset Purchase Agreement, we advanced funds to Ibeo so that it could continue its operations while in insolvency during the period between signing and closing. Specifically, in December 2022, we advanced approximately $4.1 million in operating funds, which included costs related to headcount reductions carried out by Ibeo management, decreasing the number of employees to transfer in connection with the acquisition to approximately 250 employees. These headcount reduction costs will be reimbursed to MicroVision by way of deduction from the purchase price in accordance with the Asset Purchase Agreement. We advanced an additional approximately $3.0 million to Ibeo in January 2023, a portion of which will also be reimbursed to us as a purchase price deduction.

The Company did not record any revenue during the year ended December 31, 2022 related to the Ibeo asset acquisition as the transaction closed at the end of January 2023.

We have been unable to secure the customers at the scale needed to successfully launch our products. We have incurred substantial losses since inception, and we expect to incur a significant loss during the fiscal year ending December 31, 2023.

MicroVision, Inc. was founded in 1993 as a Washington corporation and reincorporated in 2003 under the laws of the State of Delaware. Our headquarters is located at 18390 NE 68th Street, Redmond, Washington 98052, and our telephone number is (425) 936-6847.

Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports are available free-of-charge from the investor page of our website, accessible at www.microvision.com, as soon as reasonably practicable after such material is electronically filed with the Securities and Exchange Commission (SEC). Copies of these filings may also be obtained by visiting the SEC’s website, www.sec.gov, which contains current, quarterly and annual reports, proxy and information statements and other information regarding issuers that file electronically.

Our Industry and Market Strategy

We are developing our lidar sensors and perception software to address the needs of the Level 2+, or L2+, and Level 3, or L3, ADAS markets to be used in automotive safety and autonomous driving applications. Our MEMS-based high-speed lidar sensors, which we call MAVIN™, use our pioneering LBS technology. With our acquisition of Ibeo assets, we estimate our serviceable addressable market for the period 2025 to 2030 to be approximately 90 million long-range lidar sensors and 185 million short-range lidar sensors with a total cumulative potential revenue opportunity of approximately $82 billion. These estimates assume that L2+ functionality requires one long-range and two short-range lidar sensors for each vehicle and L3 functionality requires two long-range and four short-range lidar sensors for each vehicle, and that the average sales price per long-range lidar sensor is $500 and per short-range lidar sensor is $200.

Our solution-based development approach recognizes two key realities of the L2+ and L3 markets: that safety is mission-critical and that OEMs require cost efficiency and integration adaptability. With these factors in mind, we believe that our best-in-class MAVIN lidar sensors support critical safety needs by providing the highest resolution at range and velocity of moving objects with a dynamic field of view while running at 30 hertz, thus enabling ADAS features, such as automatic emergency braking, forward collision warning, and automatic emergency steering, at higher speeds of operation than most competing products. Moreover, we tailor our solution to meet the needs of OEMs, integrating our MEMS-based lidar and edge computing to support Highway Pilot capabilities up to 130km/h, save development cost and time for OEMs with no training required for our sensor-fused output, reduce system cost by requiring fewer and cheaper sensors and reduced processing, and enable seamless integration with an OEM’s existing architecture. Our unique solution for the L2+ and L3 markets, we believe, has the potential to achieve our goal of enabling mission-critical safety systems while solving for OEMs’ cost and integration objectives.

With this customer-centric approach, our go-to-market strategy depends on building partnerships with OEMs and Tier-1 automotive suppliers, as well as with silicon companies to support our solution on their compute platforms. Although we are working to establish direct marketing and co-development relationships with OEMs, we expect that our revenue may also be derived directly from Tier-1 suppliers in the form of licensing revenue.

2

##### Table of Contents

Our Technology and Competitive Strength

We believe a significant competitive strength for us today is our long history of delivering LBS- and MEMS-based hardware and related firmware and software that meets reliability, predictability, and scalability standards of well-known OEMs and ODMs.

Core to our automotive lidar sensors, custom ASICs and perception software is proprietary technology that we have been developing, refining, productizing and protecting for nearly 30 years. Our patented LBS technology combines a MEMS scanning mirror, laser diode light sources, electronics, and optics that are controlled using our proprietary system control algorithms along with edge computing and machine learning in some systems. The MEMS scanning mirror is a key component of our technology system and is one of our core competencies. Our MEMS scanning mirror is a silicon device that oscillates in a precisely controlled closed loop pattern so that we can place a pixel of light at a precise point. This allows us to generate a projected image pixel-by-pixel for use in lidar sensing and display. Scanning modules with our technology can be designed to operate in one of three different modes: lidar sensing only, display and lidar sensing combined, and display only. We believe that our proprietary technology offers significant advantages over other lidar sensing systems and traditional displays.

Early applications of our proprietary technology included heads up displays for the U.S. military and automotive systems. The contemplated uses of our technology require incorporation of our components into the products of other companies or partners. Most recently, our technology can be found in a Microsoft heads up display product. In the past, we have worked with other global brands to incorporate our core technology into their consumer products.

The MAVIN DR, our dynamic-range automotive lidar sensor is designed to, and we believe can, meet or exceed OEM specifications, performing to 220 meters of range with an output resolution of up to 15.0 million points per second. We believe that our hardware can deliver the highest point cloud density for a single-channel sensor as compared to competitive products. In addition to providing a low-latency, high-resolution point cloud at range, our sensor outputs axial, lateral, and vertical components of velocity of moving objects in the field of view at 30 hertz. This allows our solution to support a detailed understanding of the velocity of moving objects in real time, enabling fast and accurate path planning and maneuvering of the vehicle. Further, our proprietary scan locking feature ensures that our sensor is immune from interference from sunlight and from other lidar sensors.

In Augmented Reality (AR) applications, our technology enables high resolution of 1440i for large fields of view with low weight and low latency and persistence. Our Interactive Display gives an instant on and off, full color, focus-free, 720p projected image that is capable of responding as if it were a capacitance touch screen from any surface on which the projection can be seen. Our Consumer Lidar has a small size with high resolution, low power and low latency and is intended for use indoors to enable a smart home system to understand what is happening in the home and respond in an appropriate way.

Our Products and Revenue Strategy

Following our recent acquisition, our product suite includes our MEMS-based high-speed automotive lidar sensors, perception software, flash-based automotive lidar sensor, lidar sensors for non-automotive industrial markets, and reference and validation software. We also provide engineering services in connection with these hardware and software products.

Central to our development and commercialization efforts is our MAVIN DR dynamic view lidar system targeted for sale to automotive OEMs and Tier 1 automotive suppliers. MAVIN DR combines short-, medium- and long-range sensing and fields of view into one form factor. Dynamic range is key to enabling ADAS features at highway speeds. At speeds of up to 130 km/h (80 mph), ADAS systems need more time to make decisions and react in order to take proactive action and hence need resolution at range. Our MAVIN DR sensor produces an ultra-high-resolution point cloud showing drivable and non-drivable areas of the road ahead. With its low latency point cloud (30 hertz), the MAVIN product line allows ADAS systems to respond more quickly, make split-second decisions and take action at high speeds.

3

##### Table of Contents

Our perception software integrated with our automotive lidar hardware, and eventually ported into our digital ASIC, is also targeted for sale to automotive OEMs and Tier 1 automotive suppliers. This perception software, included in our acquisition of assets from Ibeo, has successfully passed through qualification processes with automotive OEMs.

Also included in our acquisition of assets are Ibeo’s sensors for the non-automotive industrial market and for the automotive market. These sensors support a revenue strategy that includes royalty revenues from automotive production, as well as sales in multiple markets including industrial, smart infrastructure, robotics, and commercial vehicles.

Our acquisition allows us to offer a system solution for validating vehicle sensors for ADAS and AV applications. The system includes software that automates the manual data classification or annotation process, significantly reducing the time and resources required by OEMs to validate their ADAS and AV systems. In addition to the auto-annotation software, sales of this validation solution may include our lidar sensors.

Beginning in the third quarter of 2019 and through the end of February 2020, we were selling components to a high-definition display system that we developed for Microsoft under a development agreement. The volume and resulting revenue and gross profit from this business was fairly low. Therefore, in March 2020, we transferred production of the components to the customer. Starting in March 2020 and through 2022, we earned a royalty from the customer for each unit shipped, with amounts applied against the prepayment that we had previously received from the customer until the prepayment is exhausted. The value of the royalty is approximately equal to the amount of gross profit we would have earned if we had continued to produce and ship the components. We believe this arrangement helps us conserve cash, while preserving our ability to experience financial benefits in the event the volume of components increases in the future.

Research and Development

We believe our research and development efforts have earned us a leadership position in the field of lidar sensors, LBS technology and applications as applied to automotive, consumer electronics and other markets. Our ability to attract customers and grow revenue will depend on our ability to maintain our technology leadership, to continually improve performance, reduce costs, and ensure functional safety and flexible design. Our research and development teams as of December 31, 2022 were located in Redmond, Washington and Nuremberg, Germany and were comprised of 90 engineering and technical staff in optics, software engineering, electrical engineering, product engineering, and MEMS design. With the closing of our acquisition on January 31, 2023, our engineering and technical staff increased to approximately 295, adding a team in Hamburg, Germany.

Sales and Marketing

Our sales and marketing approach is account based, business-to-business targeting of OEMs and Tier 1 suppliers. Our business development efforts are headed by executive management and business development representatives and are supported by engineers that assist customers during the design cycles of products. Our business development office for our automotive solution is located in Germany. We engage potential customers directly, participate in trade shows, and maintain a website.

Manufacturing

Although we are not manufacturing products at significant volume at this time, in the past, when we have produced products or components, our products were manufactured by a contract manufacturer based on our proprietary design, process, test, quality, and reliability standards and incorporated our LBS technology and included MEMS and ASICs that were produced to order by semiconductor foundries. Our past manufacturing has not been subject to seasonal variations as our shipments have been relatively small and were in the early stages of product introduction. In the future, depending on our customers’ product mix, we may be affected by seasonal fluctuations which could affect working capital demands. Many of the raw materials used in our components are standard to the consumer electronics industry. Our MEMS, MEMS die, and ASICs have historically been manufactured to our specifications by separate single-source suppliers.

4

##### Table of Contents

Competitive Conditions

Many companies are attempting to develop lidar sensors and ADAS solutions; the competitive landscape is highly crowded and rapidly evolving. We compete with pureplay lidar developers, some of which have recently completed de-SPAC transactions raising significant capital. Some of these companies have announced partnerships with OEMs, Tier 1 suppliers, and contract manufacturers that, even if nonexclusive, may appear more credible than we do in the marketplace. We also face competition from OEMs and Tier 1 suppliers that have internally developed lidar sensors. All of these OEMs and Tier 1s are significantly larger, more well-resourced, have long operating histories and enjoy relevant brand recognition. Many lidar developers are also building ADAS solutions with which our solution competes. Our competitors may succeed in developing innovative technologies and products that could render our technology or products commercially infeasible or technologically obsolete.

The lidar sensing and consumer display industries have been characterized by rapid and significant technological advances. Our LBS technology system and products may not be competitive with such advances, and we may not have sufficient funds to invest in new technologies, products or processes. Although we believe our technology system and products could deliver higher performance and have other advantages, manufacturers of competing technologies may develop improvements to their technology that could reduce or eliminate the anticipated advantages of our products.

Intellectual Property and Proprietary Rights

We create intellectual property from three sources: internal research and development activities, technology acquisitions, and performance on development contracts. The inventions covered by our patent applications generally relate to systems controls in our LBS technology, component miniaturization, power reduction, feature enhancements, specific implementation of various system components, and design elements to facilitate mass production. Protecting these key-enabling technologies and components is a fundamental aspect of our strategy to penetrate diverse markets with unique products. As such, we intend to continue to develop our portfolio of proprietary and patented technologies at the system, component, and process levels.

We believe our extensive patent portfolio is the largest, broadest, and earliest filed LBS technology portfolio. We currently have over 400 issued patents and pending patents worldwide. With the closing of the Ibeo acquisition on January 31, 2023, we added approximately 330 patents to our portfolio. As our technology develops, we periodically review our patent portfolio and eliminate patents that are deemed of low value. Due to this ongoing portfolio management practice, the number of patents in our portfolio will vary at any given time.

Since our inception in 1993, we have acquired through portfolio purchases, patents that grant us exclusive rights to various LBS technologies. From time to time some of these patents may expire or be abandoned to better utilize resources expended to maintain and generate new intellectual property.

Our ability to compete effectively in automotive lidar or any other market we may enter may depend, in part, on our ability and the ability of our licensors to maintain the proprietary nature of these technologies.

We also rely on unpatented proprietary technology. To protect our rights in these areas, we require all employees, and where appropriate, contractors, consultants, advisors and collaborators, to enter into confidentiality and non-compete agreements. There can be no assurance, however, that these agreements will provide meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, know-how or other proprietary information.

We have registered the name “MAVIN™,” “PicoP®” and “MicroVision®” with the United States Patent and Trademark Office.

Our Employees, People Operations and Workplace Safety

As of February 24, 2023, throughout our global offices, we had approximately 350 full-time employees, which included the employees who joined MicroVision in connection with our acquisition of assets from Ibeo. None of our employees are represented by a labor union or works council.

5

##### Table of Contents

Our principal objectives with respect to our workforce are to attract, retain, motivate, and reward our employees to achieve positive results for our customers and for MicroVision. To achieve these objectives, our employee benefit programs seek to (i) support skill building and prepare our employees for advancement through continuous learning, (ii) reward our employees through compensation awards and resources intended to motivate our employees and promote well-being, and (iii) continuously identify opportunities for development through regular employee input and engagement. We offer competitive compensation and benefits.

We also strive for continuous improvement in diversity and inclusivity among our employees, management, and board of directors, and seek to promote job opportunities to a diverse pool of qualified candidates. We are also committed to providing an inclusive work environment free of discrimination or harassment of any kind, supported by policies, communications, and reporting and resolution resources.

Protecting the safety, health, and well-being of our employees is also a key priority and we have implemented policies and practices to support this. Throughout the COVID-19 pandemic, we have remained focused on the health and safety of our employees by implementing appropriate safety protocols. We have implemented work-from-home procedures where possible, required the wearing of masks and physical distancing on the job when called for by local guidelines, and increased cleaning procedures and provided cleaning supplies.

We work with third party independent experts in the field of laser safety to assist in meeting safety specifications. In addition, we monitor developments in the area of permissible laser exposure limits as established by International Electrotechnical Commission (IEC) and others. Independent experts have concluded that laser exposure to the eye resulting from use of LBS devices under normal operating conditions would be below the calculated maximum permissible exposure level set by the IEC.

Continuing Impact of COVID-19 on Our Business

Our business operations continue to be impacted by the COVID-19 pandemic. Government restrictions in the early days of the pandemic caused us to mostly close our offices in early 2020. To support our hardware development efforts, we reopened our offices in July 2021 while maintaining compliance with government mandates and health agency protocols, including masking requirements and encouraging vaccination. Many of our office employees continue to work on hybrid schedules or remotely. We may experience reductions in productivity and disruptions to our business routines while our hybrid work policy remains in place, or if our employees become ill and are unable to work, which could have an adverse effect on the timing of our development and productization activities. We will continue to prioritize the health and safety of our employees as we adapt our workplace policies based on evolving government regulation, health agency advice, and industry best practice.

In addition, several of our suppliers have experienced closures or have been operating at reduced capacity, resulting in lower component availability. Continued disruptions to our supply chain could have a material impact on our development and future operations. Moreover, various global travel restrictions and office closures have hampered our business development efforts, making it more difficult to engage with potential customers and partners, which could have a material negative impact on our business prospects.

ITEM 1A. | RISK FACTORS

You should carefully consider the risks described below together with the other information set forth in this report, which could materially affect our business, financial condition and future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results.

Risk Factors Related to Our Business

We have a history of operating losses and expect to incur significant losses in the future.

We have had substantial losses since our inception. We cannot assure you that we will ever become or remain profitable.

| • |  | As of December 31, 2022, we had an accumulated deficit of $682.5 million.

| • |  | We had an accumulated deficit of $572.6 million from inception through December 31, 2019, a net loss of $13.6 million in 2020, a net loss of $43.2 million in 2021, and a net loss of $53.1 million in 2022.

6

##### Table of Contents

The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and commercialize new technologies. In particular, our operations to date have focused primarily on research and development of our LBS technology system, including products built around that technology such as our automotive lidar sensor, and development of demonstration units. We are unable to accurately estimate future revenues and operating expenses based upon historical performance.

We cannot be certain that we will succeed in obtaining development revenue or commercializing our technology or products. In light of these factors, we expect to continue to incur significant losses and negative cash flow at least through 2023 and likely thereafter. There is significant risk that we will not achieve positive cash flow at any time in the future.

We may require additional capital to fund our operations and to implement our business plan. Raising additional capital may dilute the value of current shareholders’ investment in us.

Based on our current operating plan, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months. We may, however, require additional capital to fund our operating plan past that time. We may seek to obtain additional capital through the issuance of equity or debt securities, product sales and/or licensing activities. There can be no assurance that any such efforts to obtain additional capital would be successful.

We are currently focused on developing and commercializing our automotive lidar solution. This involves introducing new technology into an emerging market which creates significant uncertainty about our ability to accurately project revenue, costs and cash flows. Our capital requirements will depend on many factors, including, but not limited to, the commercial success of our technology, the rate at which OEMs introduce systems incorporating our products and technology and the market acceptance and competitive position of such systems. Our expenses are expected to increase significantly as a result of the Ibeo acquisition and related headcount increase. If revenues are less than we anticipate, if the mix of revenues and the associated margins vary from anticipated amounts or if expenses exceed the amounts budgeted, we may require additional capital earlier than expected to fund our operations. In addition, our operating plan provides for the development of strategic relationships with suppliers of components, products and systems, and equipment manufacturers that may require additional investments by us.

Additional capital may not be available to us or, if available, may not be available on terms acceptable to us or on a timely basis. Raising additional capital may involve issuing securities with rights and preferences that are senior to our common stock and may dilute the value of our current shareholders’ investment in us. If adequate capital resources are not available on a timely basis, we may consider limiting our operations substantially and we may be unable to continue as a going concern. This limitation of operations could include reducing investments in our research and development projects, staff, operating costs, and capital expenditures which could jeopardize our ability to achieve our business goals or satisfy our customer requirements.

7

##### Table of Contents

Risks Related to our Financial Statements and Results

Our revenue is generated from one customer and losing that customer would have a negative impact on our revenue.

In 2022, one customer accounted for $664,000 in revenue, representing 100% of our total revenue. No revenue was recognized from this customer during the second half of 2022 as no shipments of our components were reported by the customer during that period. In 2021, the same customer accounted for $2.5 million in revenue, representing 100% of our total revenue. In 2020, the same customer accounted for $3.0 million in revenue, representing 97% of our total revenue. The loss of our current sole customer or the continued reporting of no shipments would negatively affect our revenue.

We have, in the past, identified a material weakness in our internal controls.

In the second quarter of 2021, we identified a material weakness in the controls that support our determination of the grant date of equity awards. If we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting obligations. Any such failure could cause investors to lose confidence in the accuracy of our financial reports, harm our reputation and adversely affect the market price of our common stock.

Our stock price has fluctuated in the past, has recently been in decline and may be volatile in the future, and as a result, investors in our common stock could incur substantial losses.

Our stock price has fluctuated significantly in the past, and may continue to be volatile in the future. Over the 52-week period ending February 24, 2023, our common stock has traded at a low of $2.11 and a high of $5.96. We may continue to experience sustained depression or substantial volatility in our stock price in the foreseeable future unrelated to our operating performance or prospects. For the fiscal year ended December 31, 2022, we incurred a loss per share of $(0.32).

As a result of this volatility, investors may experience losses on their investment in our common stock. The market price for our common stock may be influenced by many factors, including the following:

| • |  | investor reaction to our business strategy;

| • |  | the success of competitive products or technologies;

| • |  | strategic developments;

| • |  | the timing and results of our development and commercialization efforts with respect to our lidar sensors and ADAS solutions;

| • |  | changes in regulatory or industry standards applicable to our technologies;

| • |  | variations in our or our competitors’ financial and operating results;

| • |  | developments concerning our collaborations or partners;

| • |  | developments or disputes with any third parties that supply, manufacture, sell or market any of our products;

| • |  | developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technology;

| • |  | actual or perceived defects in any of our products, if commercialized, and any related product liability claims;

| • |  | our ability or inability to raise additional capital and the terms on which we raise it;

| • |  | declines in the market prices of stocks generally;

| • |  | trading volume of our common stock;

| • |  | sales of our common stock by us or our stockholders;

| • |  | general economic, industry and market conditions; and

| • |  | the effects of other events or factors, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, such as the COVID-19 outbreak, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere.

Since the price of our common stock has fluctuated in the past, has suffered recent declines and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no guarantee that our stock price will remain at current levels or that future sales of our common stock will not be at prices lower than those sold to investors.

8

##### Table of Contents

Additionally, securities of certain companies have in the past few years experienced significant and extreme volatility in stock price due to short sellers of shares of common stock, known as a “short squeeze.” These short squeezes have caused extreme volatility in both the stock prices of those companies and in the market, and have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment, as in many cases the price per share has declined steadily as interest in those stocks have abated. There can be no assurance that our shares will not be subject to a short squeeze in the future, and investors may lose a significant portion or all of their investment if they purchase our shares at a rate that is significantly disconnected from our underlying value.

If we are unable to maintain our listing on The Nasdaq Global Market, it could become more difficult to sell our stock in the public market.

Our common stock is listed on The Nasdaq Global Market. To maintain our listing on this market, we must meet Nasdaq’s listing maintenance standards. If we are unable to continue to meet Nasdaq’s listing maintenance standards for any reason, our common stock could be delisted from The Nasdaq Global Market. If our common stock were delisted, we may seek to list our common stock on The Nasdaq Capital Market, the NYSE American or on a regional stock exchange or, if one or more broker-dealer market makers comply with applicable requirements, the over-the-counter (OTC) market. Listing on such other market or exchange could reduce the liquidity of our common stock. If our common stock were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock.

A delisting from The Nasdaq Global Market and failure to obtain listing on another market or exchange would subject our common stock to so-called penny stock rules that impose additional sales practice and market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from The Nasdaq Global Market and failure to obtain listing on another market or exchange could affect the ability or willingness of broker-dealers to sell or make a market in our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market.

On February 24, 2023, the closing price of our common stock was $2.51 per share.

Our lack of financial resources relative to our competitors may limit our revenues, potential profits, overall market share or value.

Our products and solutions compete with other pureplay lidar developers, many of which have recently gone public through de-SPAC transactions and therefore have substantially greater financial resources than we have. Because of their greater resources, our competitors may develop or commercialize products more quickly than us and have access to more entrenched sales channels. This imbalance in financial resources and access could result for us in reduced revenues, lower margins or loss of market share, any of which could reduce the value of our business. Additionally, for a variety of reasons, customers may choose to purchase from suppliers that have substantially greater financial or other resources than we have.

Risks Related to Our Operations

Difficulty in qualifying a contract manufacturer, Tier 1 partner, or foundry for our products, or experiencing changes in our supply chain, could cause delays that may result in lost future revenues and damaged customer relationships.

Historically, we have relied on single or limited-source suppliers to manufacture our products. Establishing a relationship with a contract manufacturer, automotive Tier 1 partner, or foundry is a time-consuming process, as our unique technology may require significant manufacturing process adaptation to achieve full manufacturing capacity. To the extent that we are not able to establish a relationship with a contract manufacturer, Tier 1 partner, or foundry in a timely manner or at prices or on other terms that are acceptable to us, we may be unable to meet contract or production milestones. Moreover, changes in our supply chain could result in increased cost and delay and subject us to risks and uncertainties regarding, but not limited to, product warranty, product liability and quality control standards. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected or the disruption in the supply chain of components from these suppliers could cause significant delays in product deliveries, which could result in lost future revenues and damaged customer relationships.

9

##### Table of Contents

Historically, we have been dependent on third parties to develop, manufacture, sell and market products incorporating our technology.

Our business strategy for commercializing our technology in products has historically included entering into development, manufacturing, licensing, sales and marketing arrangements with OEMs, ODMs and other third parties. These arrangements reduce our level of control over production and distribution and may subject us to risks and uncertainties regarding, but not limited to, product warranty, product liability and quality control standards.

We cannot be certain that we will be able to negotiate arrangements on acceptable terms, if at all, or that these arrangements will be successful in yielding commercially viable products. If we cannot establish these arrangements, we would require additional capital to undertake such activities on our own and would require extensive manufacturing, sales and marketing expertise that we do not currently possess and that may be difficult to obtain.

In addition, we could encounter significant delays in introducing our products and technology or find that the development, manufacture or sale of products incorporating our technology would not be feasible. To the extent that we enter into development, manufacturing, licensing, sales and marketing or other arrangements, our revenues will depend upon the performance of third parties. We cannot be certain that any such arrangements will be successful.

We could face lawsuits related to our use of LBS technology or other technologies, which would be costly, and any adverse outcome could limit our ability to commercialize our technology or products.

We are aware of several patents held by third parties that relate to certain aspects of light scanning displays, 3D sensing products, and other technologies that are core to our sensor hardware. These patents could be used as a basis to challenge the validity, limit the scope or limit our ability to obtain additional or broader patent rights of our patents. A successful challenge to the validity of our patents could limit our ability to commercialize our technology or products incorporating our LBS technology and, consequently, materially reduce our ability to generate revenues. Moreover, we cannot be certain that patent holders or other third parties will not claim infringement by us with respect to current and future technology. Because U.S. patent applications are held and examined in secrecy, it is also possible that presently pending U.S. applications could eventually be issued with claims that could be infringed by our products or our technology.

The defense and prosecution of a patent suit would be costly and time-consuming, even if the outcome were ultimately favorable to us. An adverse outcome in the defense of a patent suit could subject us to significant costs, require others and us to cease selling products incorporating our technology, require us to cease licensing our technology or require disputed rights to be licensed from third parties. Such licenses, if available, would increase our operating expenses. Moreover, if claims of infringement are asserted against our future co-development partners or customers, those partners or customers may seek indemnification from us for any damages or expenses they incur.

If we fail to manage expansion effectively, our revenue and expenses could be adversely affected.

Our ability to successfully offer products incorporating our technology and implement our business plan in a rapidly evolving market requires an effective planning and management process. The growth in business and relationships with customers and other third parties has placed, and will continue to place, a significant strain on our management systems and resources. We will need to continue to improve our financial and managerial controls, reporting systems and procedures, and will need to continue to train and manage our work force. Following our substantial reduction in headcount in February 2020, the risks associated with strained resources are heightened.

We target customers that are large companies with substantial negotiating power and potentially competitive internal solutions; if we are unable to sell our products to these customers, our prospects will be adversely affected.

Our potential customers, automotive OEMs in particular, are large, multinational companies with substantial negotiating power relative to us and, in some instances, may have internal solutions that are competitive to our products. These large, multinational companies also have significant resources, which may allow them to acquire or develop competitive technologies either independently or in partnership with others. Accordingly, even after investing significant resources to develop a product, we may not secure a series production award or, even after securing a series production award, may not be able to commercialize a product on profitable terms. If our products are not selected by these large companies or if these companies develop or acquire competitive technology or negotiate terms that are disadvantageous to us, it will have an adverse effect on our business prospects.

10

##### Table of Contents

Our technology and products may be subject to environmental, health and safety regulations that could increase our development and production costs.

Our technology and products could become subject to environmental, health and safety regulations or amendments that could negatively impact our ability to commercialize our technology and products. Compliance with any such current or new regulations would likely increase the cost to develop and commercialize products, and violations may result in fines, penalties or suspension of production. If we become subject to any environmental, health, or safety laws or regulations that require us to cease or significantly change our operations to comply, our business, financial condition and operating results could be adversely affected.

Our operating results may be adversely impacted by worldwide political and economic uncertainties and specific conditions in the markets we address.

In the recent past and currently, general worldwide economic conditions have experienced a downturn due to slower economic activity, concerns about inflation, increased energy costs, decreased consumer confidence, reduced corporate profits and capital spending, and adverse business conditions. Any continuation or worsening of the current global economic and financial conditions could materially adversely affect: (i) our ability to raise, or the cost of, needed capital, (ii) demand for our current and future products, and (iii) our ability to commercialize products. Additionally, the outbreaks of wars or infectious diseases, as recently experienced, may cause an unexpected downturn in economic conditions. We cannot predict the timing, strength, or duration of any economic slowdown or subsequent economic recovery, worldwide, regionally or in the automotive or technology industries.

Because we have recently expanded and may continue expanding our international operations and using foreign suppliers, our operating results could be harmed by economic, political, regulatory and other factors in foreign countries.

During 2021, we established an office in Germany and on January 31, 2023 we completed our acquisition of Ibeo assets, with the result that we now have more employees and operations in Germany than in the U.S. In addition, we currently use foreign suppliers and plan to continue to do so to manufacture current and future components and products, where appropriate. These international operations are subject to inherent risks, which may adversely affect us, including, but not limited to:

| • |  | Political and economic instability, international terrorism and the outbreak of war, such as Russia’s invasion and continuing war against Ukraine;

| • |  | High levels of inflation, as has historically been the case in a number of countries in Asia;

| • |  | Burdens and costs of compliance with a variety of foreign laws, regulations and sanctions;

| • |  | Foreign taxes and duties;

| • |  | Changes in tariff rates or other trade, tax or monetary policies;

| • |  | Changes or volatility in currency exchange rates and interest rates;

| • |  | Global or regional health crises, such as COVID-19 or other epidemics; and

| • |  | Disruptions in global supply chains.

We have recently and may in the future make acquisitions. If we fail to successfully select, execute or integrate our acquisitions, then our business, results of operations and financial condition could be materially adversely affected.

On December 1, 2022, we entered into an Asset Purchase Agreement to acquire certain assets from Ibeo Automotive Systems GmbH. We expended significant management time and effort, as well as capital, identifying, evaluating, negotiating, and executing this transaction and, since the closing of the acquisition on January 31, 2023, we have invested additional time and capital working to integrate our new Hamburg- and Detroit-based teams and operations. We cannot guarantee that these integration efforts will be successful, that the goals of the acquisition will be realized, or that the increase to our operating expenses or cash requirements will be manageable.

In the future, we may again undertake acquisitions to add new products and technologies, acquire talent, gain new sales channels or enter into new markets or sales territories. In addition to possible stockholder approval, we may need approvals and licenses from relevant government authorities for the acquisitions and to comply with any applicable laws and regulations, which could result in increased delay and costs, and may disrupt our business strategy if we fail to do so. Furthermore, acquisitions and the subsequent integration of new assets, businesses, key personnel, customers, vendors and

11

##### Table of Contents

suppliers require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our operations. Acquired assets or businesses may not generate the financial results we expect. Acquisitions could result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, the occurrence of significant goodwill impairment charges, amortization expenses for other intangible assets and exposure to potential unknown liabilities of the acquired business. Moreover, the costs of identifying and consummating acquisitions may be significant.

Before our acquisition of assets from Ibeo, we had no experience with acquisitions or the integration of acquired technology and personnel. Failure to successfully identify, complete, manage and integrate acquisitions could materially and adversely affect our business, financial condition and results of operations and could cause our stock price to decline.

Our suppliers’ facilities could be damaged or disrupted by a natural disaster or labor strike, either of which would materially affect our financial position, results of operations and cash flows.

A major catastrophe, such as an earthquake, monsoon, flood, infectious disease including the COVID-19 virus, or other natural disaster, labor strike, or work stoppage at our suppliers’ facilities or our customers, could result in a prolonged interruption of our business. A disruption resulting from any one of these events could cause significant delays in product shipments and the loss of sales and customers, which could have a material adverse effect on our financial condition, results of operations, and cash flows.

If we are unable to obtain effective intellectual property protection for our products, processes and technology, we may be unable to compete with other companies.

Intellectual property protection for our products, processes and technology is important and uncertain. If we do not obtain effective intellectual property protection for our products, processes and technology, we may be subject to increased competition. Our commercial success will depend, in part, on our ability to maintain the proprietary nature of our key technologies by securing valid and enforceable patents and effectively maintaining unpatented technology as trade secrets.

We protect our proprietary technology by seeking to obtain United States and foreign patents in our name, or licenses to third party patents, related to proprietary technology, inventions, and improvements that may be important to the development of our business. However, our patent position involves complex legal and factual questions. The standards that the United States Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change.

Additionally, the scope of patents is subject to interpretation by courts and their validity can be subject to challenges and defenses, including challenges and defenses based on the existence of prior art. Consequently, we cannot be certain as to the extent to which we will be able to obtain patents for our new products and technology or the extent to which the patents that we already own, protect our products and technology. Reduction in scope of protection or invalidation of our licensed or owned patents, or our inability to obtain new patents, may enable other companies to develop products that compete directly with ours on the basis of the same or similar technology.

We also rely on the law of trade secrets to protect unpatented know-how and technology to maintain our competitive position. We try to protect this know-how and technology by limiting access to the trade secrets to those of our employees, contractors and partners, with a need-to-know such information and by entering into confidentiality agreements with parties that have access to it, such as our employees, consultants and business partners. Any of these parties could breach the agreements and disclose our trade secrets or confidential information, or our competitors might learn of the information in some other way. If any trade secret not protected by a patent were to be disclosed to or independently developed by a competitor, our competitive position could be negatively affected.

We could be subject to significant product liability claims that could be time-consuming and costly, divert management attention and adversely affect our ability to obtain and maintain insurance coverage.

We could be subject to product liability claims if any of the product applications are alleged to be defective or cause harmful effects. For example, because some of the scanning modules incorporating our LBS technology could scan a low power beam of colored light into the user’s eye, the testing, manufacture, marketing and sale of these products involve an inherent risk that product liability claims will be asserted against us.

12

##### Table of Contents

Additionally, any misuse of our technology or products incorporating our technology by end users or third parties that obtain access to our technology, could result in negative publicity and could harm our brand and reputation. Product liability claims or other claims related to our products or our technology, regardless of their outcome, could require us to spend significant time and money in litigation, divert management time and attention, require us to pay significant damages, harm our reputation or hinder acceptance of our products. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products and technology.

Our operations could be adversely impacted by information technology system failures, network disruptions, or cyber security breaches.

We rely on information technology systems to process, transmit, store, and protect electronic data between our employees, our customers and our suppliers. Our systems are vulnerable to damage or interruptions due to events beyond our control, including, but are not limited to, natural disasters, power loss, telecommunications failures, computer viruses, hacking, or other cyber security issues. Our system redundancy may be inadequate and our disaster recovery planning may be ineffective or insufficient to account for all eventualities. Additionally, we maintain insurance coverage to address certain aspects of cyber risks. Such insurance coverage may be insufficient to cover all losses or all claims that may arise, should such an event occur.

Loss of any of our key personnel could have a negative effect on the operation of our business.

Our success depends on our executive officers and other key personnel and on the ability to attract and retain qualified new personnel. Achievement of our business objectives will require substantial additional expertise in the areas of sales and marketing, research and product development and manufacturing. Competition for qualified personnel in these fields is intense, and the inability to attract and retain additional highly skilled personnel, or the loss of key personnel, could hinder our ability to compete effectively in the automotive or technology markets and adversely affect our business strategy execution and results of operations.

COVID-19 has had an adverse effect on our business, and the continuing COVID-19 effects on our financial position and business prospects are uncertain.

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic, which continues to spread throughout the United States and the world. We are unable to fully assess or accurately predict the impact that COVID-19 has had and may continue to have on our operations due to numerous uncertainties.

The adverse impacts of the pandemic on our business thus far and on our future financial performance include, but are not limited to:

| • |  | difficulties in our ability to raise capital,

| • |  | delays to our technology development plans and timelines,

| • |  | significant declines or delays in revenue or development efforts due to supply chain disruptions,

| • |  | obstacles or delays in meeting with potential customers and partners or entering into agreements with them, and

| • |  | challenges to our operating effectiveness resulting from employees working remotely or hybrid, or being ill and unable to work.

Risks Related to Development for the Automotive Industry

If our products and solutions are not selected for inclusion in ADAS systems by automotive OEMs or automotive Tier 1 suppliers, our future prospects will be materially and adversely affected.

Automotive OEMs and Tier 1 suppliers design and develop ADAS technology over several years, undertaking extensive testing and qualification processes prior to selecting a product such as our lidar sensor for use in a particular system, product or vehicle model because such products will function as part of a larger system or platform and must meet certain other specifications. We have invested and will continue to invest significant time and resources to have our products considered and possibly selected by OEMs or Tier 1 suppliers for use in a particular system, product or vehicle model, which is known as a “series production win” or a “series production award.” In the case of ADAS technology, a series production award would mean that our lidar sensor and/or ADAS solution had been selected for use in a particular vehicle model. However, if we are unable to achieve a series production award with respect to a particular vehicle model, we may not have an opportunity to supply our products to the automotive OEM for that vehicle model for a period of many years. In many cases, this period can be as long as five to seven or more years. If our products are not selected by an automotive OEM or our suppliers for one vehicle model or if our products are not successful in that vehicle model, it is unlikely that our product will be deployed in other vehicle models of that OEM. If we fail to win a significant number of vehicle models from one or more of automotive OEMs or their suppliers, our future business prospects will be materially and adversely affected.

The complexity of our products and the limited visibility into the various environmental and other conditions under which potential customers may use the products could result in unforeseen delays or expenses from undetected defects, errors or reliability issues in hardware or software which could reduce the market adoption of our products, damage our reputation with prospective customers, expose us to product liability and other claims, and adversely affect our operating costs.

Our products are highly technical and complex and require high standards to manufacture and may experience defects, errors or reliability issues at various stages of development. We may be unable to timely manufacture or release products, or correct problems that have arisen or correct such problems to the customer’s satisfaction. Additionally, undetected errors, defects or security vulnerabilities could result in serious injury to the end users or bystanders of technology incorporating our products, inability of customers to commercialize technology incorporating our products,

13

##### Table of Contents

litigation against us, negative publicity and other consequences. These risks are particularly prevalent in the highly competitive ADAS market. These problems may also result in claims, including class actions, against us that could be costly to defend. Our reputation or brand may be damaged as a result of these problems and potential customers may be reluctant to buy our products, which could adversely affect our financial results.

Adverse conditions in the automotive industry or the global economy more generally could have adverse effects on our results of operations.

While we make our strategic planning decisions based on the assumption that the markets we are targeting will grow, our business is dependent, in large part on, and directly affected by, business cycles and other factors affecting the global automobile industry and global economy generally. Automotive production and sales are highly cyclical and depend on general economic conditions and other factors, including consumer spending and preferences, changes in interest rates and credit availability, consumer confidence, fuel costs, fuel availability, environmental impact, governmental incentives and regulatory requirements, and political volatility, especially in energy-producing countries and growth markets. In addition, automotive production and sales can be affected by our automotive OEM customers’ ability to continue operating in response to challenging economic conditions and in response to labor relations issues, regulatory requirements, trade agreements and other factors. The volume of automotive production in North America, Europe and the rest of the world has fluctuated, sometimes significantly, from year to year, and we expect such fluctuations to give rise to fluctuations in the demand for our products. Any significant adverse change in any of these factors may result in a reduction in automotive sales and production by our automotive OEM customers and could have a material adverse effect on our business, results of operations and financial condition.

Developments in alternative technology may adversely affect the demand for our lidar technology.

Significant developments in alternative technologies, such as cameras and radar, may materially and adversely affect our business prospects in ways we do not currently anticipate. Existing and other camera and radar technologies may emerge as OEMs’ preferred alternative to our solution, which would result in the loss of competitiveness of our lidar solution. Our R&D efforts may not be sufficient to adapt to these changes in technology and our solution may not compete effectively with these alternative systems.

ADAS features may be delayed in adoption by OEMs, which would negatively impact our business prospects.

The ADAS market is fast evolving and there is generally a lack of an established regulatory framework. Vehicle regulators globally continue to consider new and enhanced emissions requirements, including electrification, to meet environmental and economic needs as well as pursue new safety standards to address emerging traffic risks. To control new vehicle prices, among other concerns, OEMs may need to dedicate technology and cost additions to new vehicle designs to meet these emissions and safety requirements and postpone the consumer cost pressures of new ADAS features. As additional safety requirements are imposed on vehicle manufacturers, our business prospects may be materially impacted.

Because the lidar and ADAS markets are rapidly evolving, it is difficult to forecast customer adoption rates, demand, and selling prices for our products and solutions.

We are pursuing opportunities in rapidly evolving markets, including technological and regulatory changes, and it is difficult to predict the timing and size of the opportunities. For example, lidar-based ADAS solutions require complex technology and because these automotive systems depend on technology from many companies, commercialization of ADAS products could be delayed or impaired on account of certain technological components of ours or others not being ready to be deployed in vehicles. In addition, the selling prices we are able to ultimately charge in the future for the products we are currently developing may be less than what we currently project. Our future financial performance will depend on our ability to make timely investments in the correct market opportunities. If one or more of these markets experience a shift in prospective customer demand, our products may not compete as effectively, if at all, and they may not be designed into commercialized products. Given the evolving nature of the markets in which we operate, it is difficult to predict customer demand or adoption rates for our products, selling prices or the future growth of our target markets. If demand does not develop or if we cannot accurately forecast it, the size of our markets, inventory requirements or future financial results will be adversely affected.

14

##### Table of Contents

Because lidar is new in the markets we are seeking to enter, our market forecasts may not materialize as anticipated.

Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not materialize as anticipated. These forecasts and estimates relating to the expected size and growth of the markets for lidar-based technology may prove to be inaccurate. Even if these markets experience the forecasted growth we anticipate, we may not grow our business at similar rates, or at all. Our future growth is subject to many factors, including market adoption of our products, which is subject to many risks and uncertainties. Accordingly, we cannot assure you that these forecasts will not be materially inaccurate.

ITEM 1B. | UNRESOLVED STAFF COMMENTS

None.

ITEM 2. | PROPERTIES

In July 2017, we entered into a 65-month facility lease amendment on 31,142 square feet of combined-use office, laboratory and manufacturing space at our headquarters facility in Redmond, Washington.

In September 2021, we entered into a lease on approximately 16,681 square feet of space located in Redmond, Washington that we use primarily for general office space, lab space and product testing. The lease provides for an initial term of 128 months that commenced November 1, 2021.

In September 2021, we entered into a second lease on approximately 36,062 square feet of space located in Redmond, Washington that we will use primarily for general office space. The lease provides for an initial term of 120 months and commenced on December 1, 2022.

In connection with the effectiveness of the second lease entered into in September 2021, we amended our current office lease and will have access until January 31, 2023 to coincide with our move into the new 36,062 square feet of space.

In April 2022, we entered into a lease on approximately 3,533 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced May 1, 2022.

In September 2022, we entered into a lease on approximately 3,810 square feet of space located in Nuremberg, Germany that we use primarily for lab space and engineering activities. The lease provides for a term of 60 months that commenced November 15, 2022.

In connection with our January 2023 acquisition of assets from Ibeo, we assumed three leases in Hamburg, Germany covering approximately 45,208 square feet of office space, garages to house test and demonstration vehicles, space for IT network equipment, and long-range laser testing space.

ITEM 3. | LEGAL PROCEEDINGS

We are subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently party to any other legal proceedings that management believes are reasonably possible to have a material adverse effect on our financial position, results of operations or cash flows.

ITEM 4. | MINE SAFETY DISCLOSURES

Not applicable.

ITEM 4A. | EXECUTIVE OFFICERS OF THE REGISTRANT

Executive officers are appointed by our Board of Directors and hold office until their successors are elected and duly qualified. The following persons serve as executive officers of MicroVision, Inc.:

Sumit Sharma, age 49, was appointed Chief Executive Officer in February 2020 and served as Chief Operating Officer from June 2018 to February 2020, after serving as Vice President of Product Engineering and Operations since February 2017 and Vice President and Senior Director of Operations since September 2015. Prior to MicroVision,

15

##### Table of Contents

from April 2015 to September 2015, he was a Product Development and Operations consultant at BlueMadison Consulting. From November 2013 to March 2015, he was the Senior Director, Advanced Manufacturing Operations and Technology Development at Jawbone. From March 2011 to October 2013, he was the Head of Manufacturing Operations for project GLASS at Google. Mr. Sharma has extensive experience in optics, wearable technology, product development and qualification for automotive industry. Mr. Sharma also has deep experience in global operations and developing strategic partnerships. A patent holder, Mr. Sharma received his baccalaureate degree in engineering from New Jersey Institute of Technology.

Anubhav Verma, age 37, joined MicroVision in November 2021 as Chief Financial Officer. Prior to MicroVision, from October 2016 to November 2021, he led several growth initiatives including M&A and Capital Market transactions as Senior Vice President Finance of Exela Technologies. From November 2013 to October 2016, he was an Investment Professional of HandsOn Global Management driving end-to-end M&A deals including post-merger integration along with several rounds of capital market financings. From July 2009 to October 2013, he advised several Fortune 500 companies as an Investment Banker at Credit Suisse in their New York and Mumbai offices. Mr. Verma has extensive experience in Mergers and Acquisitions (M&A), Capital Markets and Strategic Finance roles for publicly listed and privately held companies. Mr. Verma received a Bachelor of Technology degree in engineering and a Masters of Technology degree in engineering from the Indian Institute of Technology, Bombay.

Drew Markham, age 55, joined MicroVision in June 2021 as Vice President, General Counsel and Secretary. Before joining MicroVision, from January 2017 through June 2021, Ms. Markham was President at Avisé, a social purpose corporation, where she was a legal consultant to publicly traded technology companies. From January 2013 to December 2016, she was Vice President, Deputy General Counsel & Assistant Secretary at RealNetworks, Inc. From June 1999 to December 2012, she was an attorney with Wilson Sonsini Goodrich & Rosati. Ms. Markham received her Juris Doctor degree from the University of Washington School of Law and her Bachelor of Science degree in Accounting from the University of Florida.

PART II.

ITEM 5. | MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock began trading publicly on August 27, 1996. Our common stock trades on The Nasdaq Global Market under the ticker symbol “MVIS.” We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain all future earnings to fund the operations of our business and do not anticipate paying dividends on the common stock in the foreseeable future.

As of February 24, 2023, there were approximately 128 holders of record of 175,818,617 shares of common stock outstanding. As many of our shares of common stock are held by brokerages and institutions on behalf of shareholders, we are unable to estimate the total number of beneficial holders of our common stock represented by these record holders.

Stock Performance Graph

This performance graph shall not be deemed to be “soliciting material” or “filed” or incorporated by reference in future filings with the Securities and Exchange Commission, or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The following graph shows a comparison from 2017 through 2022 of the cumulative total return for our common stock, the Russell 2000 Index, the NASDAQ Electrical Components Index and the Dow Jones US Electronic and Electrical Equipment Index. The NASDAQ Electrical Components Index has been discontinued. The comparisons in the graph are historical and are not intended to forecast or be indicative of possible future performance of our common stock.

16

##### Table of Contents

ITEM 6. | RESERVED

ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and the related notes included in Part II, Item 8 of this Form 10-K. The following discussion focuses on the results of our operations for the year ended December 31, 2022 compared to the year ended December 31, 2021. Similar discussion of the results of our operations for the year ended December 31, 2021 compared to the year ended December 31, 2020 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021.

Overview

Currently, our development efforts are primarily focused on automotive lidar sensors and perception software for ADAS applications. Our integrated solution will combine our MEMS-based lidar sensor, custom ASICs, and software targeted for sale to automotive OEMs and Tier 1 automotive suppliers. We are forecasting small quantities of sales in 2023, but we do not expect to achieve significant, sustained revenue from our ADAS solution in the near term.

Although automotive lidar is our priority now, we have developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. For the past few years, our strategy has been to sell AR displays or components, Interactive Displays, or Consumer Lidars to original equipment manufacturers (OEMs) and original design manufacturers (ODMs) for incorporation into their products. Currently, our sole customer is Microsoft Corporation. Our arrangement with this customer generates royalty income; however, the volume of sales and resulting royalties from that arrangement are not significant. In the recent past, we have been unable to secure additional customers to launch one of our products.

17

##### Table of Contents

We have incurred substantial losses since inception and expect to incur a significant loss during the fiscal year ending December 31, 2023. We have funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales and licensing activities. There can be no assurance that additional capital will be available or that, if available, it will be available on terms acceptable to us on a timely basis. We cannot be certain that we will succeed in commercializing our technology or products.

Continuing Impact of COVID-19 on Our Business

Our business operations continue to be impacted by the ongoing COVID-19 pandemic. Government restrictions in the early days of the pandemic caused us to mostly close our offices in early 2020. To support our hardware development efforts, we reopened our offices in July 2021 while maintaining compliance with government mandates and health agency protocols, including masking requirements and encouraging vaccination. Some of our office employees continue to work remotely or on hybrid schedules. We may experience reductions in productivity and disruptions to our business routines while our hybrid work policy remains in place, or if our employees become ill and are unable to work, which could have an adverse effect on the timing of our development and productization activities. We will continue to prioritize the health and safety of our employees as we adapt our workplace policies based on evolving government regulation, health agency advice, and industry best practice.

In addition, several of our suppliers have experienced closures or have been operating at reduced capacity, resulting in lower component availability. Continued disruptions to our supply chain could have a material impact on our development and future operations. Moreover, various global travel restrictions and office closures have hampered our business development efforts, making it more difficult to engage with potential customers and partners, which could have a material negative impact on our business prospects.

Key accounting policies and estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that materially affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. We evaluate our estimates on a continuous basis. We base our estimates on historical data, terms of existing contracts, our evaluation of trends in the consumer display and 3D sensing industries, information provided by our current and prospective customers and strategic partners, information available from other outside sources and on various other assumptions we believe to be reasonable under the circumstances. The results form the basis for making judgments regarding the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following key accounting policies require significant judgments and estimates used in the preparation of our consolidated financial statements.

Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to our customers, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We generate all of our revenue from contracts with customers.

Our contract revenue in a particular period is dependent upon when we enter into a contract, the value of the contracts we have entered into, and the availability of technical resources to perform work on the contracts. We recognize contract revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) occur over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. In contracts that include significant customer acceptance provisions, we recognize revenue only upon acceptance of the deliverable(s).

We identify each performance obligation in our development contracts at contract inception. The contracts generally include product development and customization specified by the customer. In contracts with multiple performance obligations, we identify each performance obligation and evaluate whether the performance obligations are distinct within the context of the contract. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Performance obligations that are not distinct at contract inception are combined.

18

##### Table of Contents

If we identify multiple distinct performance obligations, we evaluate each performance obligation to determine if there is a stand-alone selling price. In instances where stand-alone selling price is not directly observable, such as when we do not sell the product or service separately, we determine the stand-alone selling price using information that may include market conditions and other observable inputs. Judgment is required to determine the stand-alone selling price for each distinct performance obligation.

Our development contracts are primarily fixed-fee contracts. If control of deliverables occurs over time, we recognize revenue on fixed fee contracts on the proportion of total cost expended (under Topic 606, the ‘input method’) to the total cost expected to complete the contract performance obligation. For contracts that require the input method for revenue recognition, the determination of the total cost expected to complete the performance obligations on fixed fee contracts involves significant judgment. We incorporate revisions to hour and cost estimates when the causal facts become known.

Share-based compensation

We issue share-based compensation to employees in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for the share-based awards by recognizing the fair value of share-based compensation expense on a straight-line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black-Scholes option pricing model. The fair value of RSUs and non-executive PSUs is determined by the closing price of our common stock on the grant date. For performance-based awards, expense is recognized when it is probable the performance criteria will be achieved. If the likelihood becomes improbable that the performance criteria will be achieved, the expense is reversed. Executive PSUs that have market-based performance criteria are valued using a binomial option pricing model using the following inputs: stock price, volatility, and risk-free interest rates. Changes in estimated inputs or using other option valuation methods may result in materially different option values and share-based compensation expense.

Leases

Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and non-lease components, and the determination of the discount rate included in our office lease. We review the underlying objective of each contract, the terms of the contract, and consider our current and future business conditions when making these judgments.

Income taxes

Significant judgment is required in evaluating our tax position and in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. Based on our history of losses since inception, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets. Our actual tax exposure may differ from our estimates and any such differences may impact income our tax expense in the period in which such determination is made.

The key accounting policies described above are not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for us to apply judgment or make estimates. There are also areas in which our judgment in selecting any available alternative would not produce a materially different result to our consolidated financial statements. Additional information about our accounting policies, and other disclosures required by generally accepted accounting principles, are set forth in the notes to our consolidated financial statements.

Results of Operations

YEAR ENDED DECEMBER 31, 2022 COMPARED TO YEAR ENDED DECEMBER 31, 2021.

License and royalty revenue

19

##### Table of Contents

|  | 2022 |  |  | % of total revenue |  |  | 2021 |  |  | % of total revenue |  |  | $ change |  |  | % change |
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License and royalty revenue |  | $ | 664 |  |  |  | 100.0 |  |  | $ | 2,500 |  |  |  | 100.0 |  |  | $ | (1,836 | ) |  |  | (73.4 | )

License and royalty revenue is revenue under license agreements to our PicoP® scanning technology. We recognize revenue on upfront license fees at a point in time if the nature of the license granted is a right-to-use license, representing functional intellectual property with significant standalone functionality. If the nature of the license granted is a right-to-access license, representing symbolic intellectual property, which excludes significant standalone functionality, we recognize revenue over the period of time we have ongoing obligations under the agreement. We will recognize revenue from sales-based royalties on the basis of the quarterly reports provided by our customer as to the number of royalty-bearing products sold or otherwise distributed. In the event that reports are not received, we will estimate the number of royalty-bearing products sold by our customers.

As described above, in March 2020, our customer took over production of components that we had been producing for them. As a result, beginning in March 2020, we earn a royalty on each component shipped that is approximately equal to the gross profit we would have earned if we had continued to produce and ship the components. The decrease in license and royalty revenue for year ended December 31, 2022 compared to the same period in 2021 was due to a lower number of royalty-bearing products being communicated to us as distributed by our customer. As we recognize this revenue, we record a corresponding reduction in the $10.0 million prepayment that we received from this customer in 2017; accordingly, no cash will be received for this royalty revenue unless and until the prepayment is exhausted.

Cost of product revenue

|  |  |  |  | % of |  |  |  |  |  | % of |  |  |  |  |  |  |
|  |  |  |  | product |  |  |  |  |  | product |  |  |  |  |  |  |
|  | 2022 |  |  | revenue |  |  | 2021 |  |  | revenue |  |  | $ change |  |  | % change |
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of product revenue |  | $ | 100 |  |  |  | n/a |  |  | $ | 2 |  |  |  | n/a |  |  | $ | 98 |  |  |  | 4,900.0 |

Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged to us by our contract manufacturers, in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with operating our manufacturing capabilities and capacity. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based on the proportion of indirect labor which supported production activities.

Cost of product revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of manufacturing overhead expense and the volume of direct material purchased. Cost of product revenue was higher during the twelve months ended December 31, 2022 compared to the same period in 2021 due to inventory write-downs for obsolete materials.

Research and development expense

|  | 2022 |  |  | 2021 |  |  | $ change |  |  | % change |
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | $ | 30,413 |  |  | $ | 24,111 |  |  | $ | 6,302 |  |  |  | 26.1 |

Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. We believe that a substantial level of continuing research and development expense will be required to further develop our scanning technology.

20

##### Table of Contents

The increase in research and development expense during the year ended December 31, 2022 was primarily due to higher personnel costs as a result of increased headcount of $3.9 million, higher facilities expenses of $1.1 million higher non-cash compensation expense of $808,000 and higher purchased labor of $542,000 compared to the prior year.

Sales, marketing, general and administrative expense

|  | 2022 |  |  | 2021 |  |  | $ change |  |  | % change |
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |
Sales, marketing, general and administrative expense |  | $ | 24,041 |  |  | $ | 22,256 |  |  | $ | 1,785 |  |  |  | 8.0 |

Sales, marketing, general and administrative expense includes compensation and support costs for marketing, sales, management and administrative staff, and for other general and administrative costs, including legal and accounting services, consultants and other operating expenses.

The increase in sales, marketing, general and administrative expense during the year ended December 31, 2022 was primarily attributed to increased salary and benefits expenses as a result of increased headcount of approximately $1.5 million, higher professional services of $1.0 million and increased business insurance of $1.0 million compared to the prior year, offset by lower consulting expenses of $1.4 million and lower non-cash compensation of $631,000.

Income taxes

No provision for income taxes has been recorded because we have experienced net losses from inception through December 31, 2022. At December 31, 2022, we had net operating loss carryforwards of approximately $440.3 million for federal income tax reporting purposes. In addition, we have research and development tax credits of $9.6 million. During 2022, $22.0 million federal net operating losses expired unused. A majority of the net operating loss carryforwards and research and development credits available to offset future taxable income, if any, will expire in varying amounts from 2023 to 2042, if not previously used.

In certain circumstances, as specified in the Internal Revenue Code, a 50% or more ownership change by certain combinations of our shareholders during any three-year period would result in a limitation on our ability to use a portion of our net operating loss carryforwards.

We recognize interest accrued and penalties related to unrecognized tax benefits in tax expense. We did not have any unrecognized tax benefits at December 31, 2022 or at December 31, 2021.

Liquidity and Capital Resources

We have incurred significant losses since inception. We have funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales, and licensing activities. At December 31, 2022, we had $20.5 million in cash and cash equivalents and $62.2 million in investment securities.

Between the effectiveness of the Asset Purchase Agreement, December 1, 2022, and the closing of the acquisition, January 31, 2023, we advanced operating funds to Ibeo totaling approximately EUR 6.6 million or approximately $7.1 million to support its ongoing operations while in insolvency. These funds included costs incurred by Ibeo to reduce its headcount so that only approximately 250 employees would transfer to MicroVision upon closing of the acquisition. The costs related to the headcount reductions will be reimbursed to MicroVision by way of deduction from the purchase price per the Asset Purchase Agreement. In addition, at closing, MicroVision paid EUR 7.0 million or approximately $7.6 million to Ibeo and EUR 3.0 million or $3.3 million to an escrow account to be available to cover properly established claims by MicroVision. We expect to make the remaining final payment during the second quarter of 2023.

As of January 31, 2023, we had $18.5 million in cash and cash equivalents and $59.2 million in investment securities after making the payments to Ibeo as described above, but excluding the expected impact of the noted final payment that we expect to make in the second quarter. Based on our current operating plan for 2023 and beyond, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months.

21

##### Table of Contents

Operating activities

Cash used in operating activities totaled $38.0 million during 2022, compared to $29.4 million in 2021. Cash used in operating activities resulted primarily from cash used to fund our net loss, after adjusting for non-cash charges such as share-based compensation, depreciation and amortization charges and changes in operating assets and liabilities. The changes in cash used in operating activities were primarily attributed to increased operating expenses to support the development of our lidar sensor and software solution.

Investing activities

Cash used in investing activities totaled $38.1 million in 2022, compared to cash provided by investing activities of $35.3 million in 2021. During the year ended December 31, 2022, we purchased short-term investment securities totaling $90.2 million and sold short-term investment securities totaling $60.6 million. During the year ended December 31, 2021, we purchased short-term investment securities totaling $32.8 million. In 2022, operating funds advances to Ibeo during the pre-closing period totaling $4.1 million were included in cash used in investing activities. Purchases of property and equipment during the twelve months ended December 31, 2022 and 2021 were $4.4 million and $2.5 million, respectively. The increase in 2022 was primarily due to one-time $2.2 million investment in tenant improvements for build-out construction for our new HQ office and lab space in Redmond, WA. We expect to recover this investment through the contractual incentive payment agreed to be paid by the new incoming tenant for timely exiting our old headquarters in Redmond, WA.

Financing activities

Cash provided by financing activities totaled $14.3 million in 2022, compared to $131.2 million in 2021. During the year ended December 31, 2022, we made principal payments under long-term debt totaling $392,000 related to the loan under the Paycheck Protection Program of the 2020 CARES Act (PPP) administered by the Small Business Administration compared to $488,000 in the prior year. Proceeds received from stock option exercises totaled $726,000 during 2022 compared to $2.7 million during 2021. Principal payments under finance leases were $26,000 in 2022 and $28,000 in 2021.

The following is a list of our financing activities during 2022 and 2021.

| • |  | In June 2021, we entered into a $140.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we are able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $140.0 million through Craig-Hallum. As of December 31, 2021, we had issued 4.0 million shares of our common stock for net proceeds of $67.8 million under this ATM agreement. In 2022, we issued 4.3 million shares of our common stock for net proceeds of $14.0 million under this ATM agreement. In January 2023, we issued 5.0 million shares of our common stock for net proceeds of $12.5 million under the agreement. As of February 28, 2023, we have approximately $43.5 million available under this ATM agreement.

| • |  | In February 2021, we entered into a $50.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $50.0 million through Craig-Hallum. We issued 2.5 million shares of our common stock for net proceeds of $48.8 million under this ATM agreement. No further shares are available for sales under this agreement.

| • |  | In December 2020, we entered into a $13.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able to, from time to time, at our discretion offer and sell shares of our common stock having an aggregate value of up to $13.0 million through Craig-Hallum. As of December 31, 2020, we had issued 1.0 million shares for net proceeds of $6.1 million that was received in January 2021. The $6.1 million was classified as subscriptions receivable on our December 31, 2020 balance sheet and is not included in the cash balance as of December 31, 2020. In January 2021, we issued 1.1 million shares of our common stock for net proceeds of $6.6 million under the agreement. In total, we issued 2.1 million shares of our common stock for net proceeds of $12.7 million under this ATM agreement. No further shares are available for sales under this agreement.

Our capital requirements will depend on many factors, including, but not limited to, the rate at which OEMs and other potential customers introduce products incorporating our technology and the market acceptance and competitive position of such products. Our ability to raise capital will depend on numerous factors, including the following:

22

##### Table of Contents

| • |  | Perceptions of our ability to continue as a going concern;

| • |  | Market acceptance of products incorporating our technology;

| • |  | Changes in evaluations and recommendations by any securities analysts following our stock or our industry generally;

| • |  | Announcements by other companies in our industry;

| • |  | Changes in business or regulatory conditions;

| • |  | Announcements or implementation by our competitors of technological innovations or new products;

| • |  | The status of particular development programs and the timing of performance under specific development agreements;

| • |  | Economic and stock market conditions;

| • |  | The cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

| • |  | Our ability to establish cooperative development or licensing arrangements; or

| • |  | Other factors unrelated to our company or industry.

If we are successful in establishing OEM co-development arrangements, we may receive full or partial funding for certain non-recurring engineering costs for technology development and/or product development. Nevertheless, we expect our capital requirements to remain high as we expand our activities and operations with the objective of commercializing our technology.

Contractual obligations

The following table lists our contractual obligations as of December 31, 2022 (in thousands):

|  | Payments Due By Period |
Contractual Obligations |  | < 1 year |  |  | 1-3 years |  |  | 3-5 years |  |  | > 5 years |  |  | Total |
Open purchase obligations * |  | $ | 2,068 |  |  | $ | 49 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,117 |
Minimum payments under finance leases |  |  | 21 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 21 |
Minimum payments under operating leases+ |  |  | 1,903 |  |  |  | 3,843 |  |  |  | 3,980 |  |  |  | 9,663 |  |  |  | 19,389 |
|  | $ | 3,992 |  |  | $ | 3,892 |  |  | $ | 3,980 |  |  | $ | 9,663 |  |  | $ | 21,527 |

* | Open purchase obligations represent commitments to purchase materials, capital equipment, maintenance agreements and other goods used in the normal operation of our business.

Recent accounting pronouncements

See Note 2, “Summary of significant accounting policies,” in the Notes to the consolidated financial statements found in Part II, Item 8 of this Form 10-K.

ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate and Market Liquidity Risks

As of December 31, 2022, all of our cash and cash equivalents have variable interest rates; however, we believe our exposure to market and interest rate risks is not material. Due to the generally short-term maturities of our investment securities, we believe that the market risk arising from our holdings of these financial instruments is not significant. We do not believe that inflation has had a material effect on our business, financial condition or results of operations; however, we do anticipate our labor costs to increase as a result of inflationary pressures.

Our investment policy generally directs that the investment managers should select investments to achieve the following goals: principal preservation, adequate liquidity, and return. As of December 31, 2022, our cash and cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts and our short-term investments are comprised of highly rated corporate and government debt securities (A rated securities and above). The values of cash and cash equivalents and investment securities, available-for-sale as of December 31, 2022, are as follows (in thousands):

23

##### Table of Contents

|  | Amount |  |  | Percent |
Cash and cash equivalents |  | $ | 20,536 |  |  |  | 24.8 | %
Less than one year |  |  | 62,173 |  |  |  | 75.2 |
|  | $ | 82,709 |  |  |  | 100.0 | %

Foreign Exchange Rate Risk

Our major contract and collaborative research and development agreements, product sales, and licensing activity payments are currently made in U.S. dollars. However, in the future we may enter into contracts or collaborative research and development agreements in foreign currencies that may subject us to foreign exchange rate risk. We have entered into purchase orders and supply agreements in foreign currencies in the past and may enter into such arrangements, from time to time, in the future. We believe our exposure to currency fluctuations related to these arrangements is not material. We may enter into foreign currency hedges to offset material exposure to currency fluctuations when we can adequately determine the timing and amounts of the exposure.

24

##### Table of Contents

2022-12-31 2041-12-31

ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

|  | Page |
Report of Independent Registered Public Accounting Firm (Moss Adams LLP, Seattle, Washington, PCAOB ID:659) |  |  | 26 |
Consolidated Balance Sheets as of December 31, 2022 and 2021 |  |  | 27 |
Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020 |  |  | 28 |
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020 |  |  | 29 |
Consolidated Statements of Shareholders’ Equity (Deficit) for the years ended December 31, 2022, 2021 and 2020 |  |  | 30 |
Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020 |  |  | 3 1 |
Notes to Consolidated Financial Statements |  |  | 3 2 |

2
5

Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of
MicroVision, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of MicroVision, Inc. (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, shareholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and schedule (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1, 2023, expressed an unqualified opinion on the Company’s internal control over financial reporting.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.
/s/ Moss Adams LLP
Seattle, Washington
March 1, 2023
We have served as the Company’s auditor since 2012.
26

MicroVision, Inc.
Consolidated Balance Sheets
(In thousands)

|  | December 31, |
Assets |  | 2022 |  |  | 2021 |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 20,536 |  |  | $ | 82,647 |
Investment securities, available-for-sale |  |  | 62,173 |  |  |  | 32,720 |
Inventory |  |  | 1,861 |  |  |  | 1,780 |
Advance to Ibeo |  |  | 4,132 |  |  |  | — |
Other current assets |  |  | 2,306 |  |  |  | 2,283 |
Total current assets |  |  | 91,008 |  |  |  | 119,430 |
Property and equipment, net |  |  | 6,830 |  |  |  | 3,026 |
Operating lease right-of-use asset |  |  | 14,579 |  |  |  | 5,577 |
Restricted cash |  |  | 1,418 |  |  |  | 1,092 |
Intangible assets, net |  |  | 75 |  |  |  | 115 |
Other assets |  |  | 1,086 |  |  |  | 985 |
Total assets |  | $ | 114,996 |  |  | $ | 130,225 |
Liabilities and shareholders’ equity |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 2,061 |  |  | $ | 3,584 |
Accrued liabilities |  |  | 2,058 |  |  |  | 1,170 |
Contract liabilities |  |  | 4,601 |  |  |  | 5,265 |
Other current liabilities |  |  | 839 |  |  |  | 1,181 |
Current portion of long-term debt |  |  | — |  |  |  | 392 |
Current portion of operating lease liability |  |  | 1,846 |  |  |  | 849 |
Current portion of finance lease obligations |  |  | 21 |  |  |  | 21 |
Total current liabilities |  |  | 11,426 |  |  |  | 12,462 |
Operating lease liability, net of current portion |  |  | 13,829 |  |  |  | 4,983 |
Finance lease obligations, net of current portion |  |  | — |  |  |  | 26 |
Total liabilities |  |  | 25,255 |  |  |  | 17,471 |
Commitments and contingencies (Note 12) |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |
Preferred stock, par value $0.001; 25,000 shares authorized; zero and zero shares issued and outstanding, respectively |  |  | — |  |  |  | — |
Common stock, par value $0.001; 210,000 shares authorized; 170,503 and 164,363 shares issued and outstanding at December 31, 2022 and 2021, respectively |  |  | 171 |  |  |  | 164 |
Additional paid-in capital |  |  | 772,221 |  |  |  | 742,042 |
Accumulated other comprehensive loss |  |  | (127 | ) |  |  | (19 | )
Accumulated deficit |  |  | (682,524 | ) |  |  | (629,433 | )
Total shareholders’ equity |  |  | 89,741 |  |  |  | 112,754 |
Total liabilities and shareholders’ equity |  | $ | 114,996 |  |  | $ | 130,225 |

The accompanying notes are an integral part of these consolidated financial statements.
27

MicroVision, Inc.
Consolidated Statements of Operations
(In thousands, except per share data)

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Product revenue |  | $ | — |  |  | $ | — |  |  | $ | 1,347 |
License and royalty revenue |  |  | 664 |  |  |  | 2,500 |  |  |  | 1,718 |
Contract revenue |  |  | — |  |  |  | — |  |  |  | 25 |
Total revenue |  |  | 664 |  |  |  | 2,500 |  |  |  | 3,090 |
Cost of product revenue |  |  | 100 |  |  |  | 2 |  |  |  | 1,394 |
Cost of contract revenue |  |  | — |  |  |  | — |  |  |  | 4 |
Total cost of revenue |  |  | 100 |  |  |  | 2 |  |  |  | 1,398 |
Gross profit |  |  | 564 |  |  |  | 2,498 |  |  |  | 1,692 |
Research and development expense |  |  | 30,413 |  |  |  | 24,111 |  |  |  | 9,840 |
Sales, marketing, general and administrative expense |  |  | 24,041 |  |  |  | 22,256 |  |  |  | 5,917 |
Gain on disposal of fixed assets |  |  | — |  |  |  | — |  |  |  | (450 | )
Total operating expenses |  |  | 54,454 |  |  |  | 46,367 |  |  |  | 15,307 |
Loss from operations |  |  | (53,890 | ) |  |  | (43,869 | ) |  |  | (13,615 | )
Gain on debt extinguishment |  |  | — |  |  |  | 692 |  |  |  | — |
Other income (expense), net |  |  | 799 |  |  |  | (23 | ) |  |  | (19 | )
Net loss |  | $ | (53,091 | ) |  | $ | (43,200 | ) |  | $ | (13,634 | )
Net loss per share - basic and diluted |  | $ | (0.32 | ) |  | $ | (0.27 | ) |  | $ | (0.10 | )
Weighted-average shares outstanding - basic and diluted |  |  | 165,958 |  |  |  | 160,662 |  |  |  | 139,829 |

The accompanying notes are an integral part of these consolidated financial statements.
28

MicroVision, Inc.
Consolidated Statements of Comprehensive Loss
(In thousands)

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Net loss |  | $ | (53,091 | ) |  | $ | (43,200 | ) |  | $ | (13,634 | )
Other comprehensive loss |  |  |  |  |  |  |  |  |  |  |  |
Unrealized loss on investment securities, available-for-sale |  |  | (108 | ) |  |  | (19 | ) |  |  | — |
Comprehensive loss |  | $ | (53,199 | ) |  | $ | (43,219 | ) |  | $ | (13,634 | )

The accompanying notes are an integral part of these consolidated financial statements.
29

MicroVision, Inc.
Consolidated Statements of Shareholders’ Equity (Deficit)
(In thousands)

|  |  |  |  |  |  |  | Additional |  |  |  |  |  | Accumulated |  |  |  |  |  | Total |
|  | Common Stock |  |  | paid-in |  |  | Subscriptions |  |  | other |  |  | Accumulated |  |  | shareholders’ |
|  | Shares |  |  | Par value |  |  | capital |  |  | receivable |  |  | comprehensive loss |  |  | deficit |  |  | equity (deficit) |
Balance at December 31, 2019 |  |  | 125,803 |  |  |  | 126 |  |  |  | 568,496 |  |  |  | — |  |  |  | — |  |  |  | (572,599 | ) |  |  | (3,977 | )
Share-based compensation expense |  |  | 201 |  |  |  | — |  |  |  | 1,252 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,252 |
Exercise of options |  |  | 693 |  |  |  | 1 |  |  |  | 999 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,000 |
Sales of common stock, net of issuance costs |  |  | 26,229 |  |  |  | 26 |  |  |  | 30,477 |  |  |  | (6,135 | ) |  |  | — |  |  |  | — |  |  |  | 24,368 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (13,634 | ) |  |  | (13,634 | )
Balance at December 31, 2020 |  |  | 152,926 |  |  |  | 153 |  |  |  | 601,224 |  |  |  | (6,135 | ) |  |  | — |  |  |  | (586,233 | ) |  |  | 9,009 |
Share-based compensation expense |  |  | 2,365 |  |  |  | 2 |  |  |  | 15,282 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,284 |
Exercise of options |  |  | 1,518 |  |  |  | 2 |  |  |  | 2,652 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,654 |
Sales of common stock, net of issuance costs |  |  | 7,554 |  |  |  | 7 |  |  |  | 122,884 |  |  |  | 6,135 |  |  |  | — |  |  |  | — |  |  |  | 129,026 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (43,200 | ) |  |  | (43,200 | )
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (19 | ) |  |  | — |  |  |  | (19 | )
Balance at December 31, 2021 |  |  | 164,363 |  |  | $ | 164 |  |  | $ | 742,042 |  |  | $ | — |  |  |  | (19 | ) |  | $ | (629,433 | ) |  | $ | 112,754 |
Share-based compensation expense |  |  | 1,294 |  |  |  | 1 |  |  |  | 15,460 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,461 |
Exercise of options |  |  | 525 |  |  |  | 1 |  |  |  | 725 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 726 |
Sales of common stock, net of issuance costs |  |  | 4,321 |  |  |  | 5 |  |  |  | 13,994 |  |  |  |  |  |  |  | — |  |  |  | — |  |  |  | 13,999 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (53,091 | ) |  |  | (53,091 | )
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (108 | ) |  |  | — |  |  |  | (108 | )
Balance at December 31, 2022 |  |  | 170,503 |  |  | $ | 171 |  |  | $ | 772,221 |  |  | $ | — |  |  |  | (127 | ) |  | $ | (682,524 | ) |  | $ | 89,741 |

The accompanying notes are an integral part of these consolidated financial statements.
3
0

MicroVision, Inc.
Consolidated Statements of Cash Flows
(In thousands)

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Cash flows from operating activities |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (53,091 | ) |  | $ | (43,200 | ) |  | $ | (13,634 | )
Adjustments to reconcile net loss to net cash used in operations: |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 2,246 |  |  |  | 1,464 |  |  |  | 963 |
Impairment of property and equipment |  |  | 64 |  |  |  | 882 |  |  |  | — |
Gain on disposal of property and equipment |  |  | — |  |  |  | — |  |  |  | (450 | )
Share-based compensation expense |  |  | 15,461 |  |  |  | 15,284 |  |  |  | 1,297 |
Non-cash interest (income) expense |  |  | — |  |  |  | (10 | ) |  |  | 11 |
Inventory write-downs |  |  | 87 |  |  |  | 48 |  |  |  | 168 |
Net accretion of premium on short-term investments |  |  | 21 |  |  |  | 86 |  |  |  | — |
Gain on debt extinguishment |  |  | — |  |  |  | (692 | ) |  |  | — |
Change in: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | — |  |  |  | — |  |  |  | 1,079 |
Inventory |  |  | (168 | ) |  |  | (1,828 | ) |  |  | 24 |
Other current and non-current assets |  |  | (217 | ) |  |  | (2,552 | ) |  |  | 154 |
Accounts payable |  |  | (1,737 | ) |  |  | 2,520 |  |  |  | (1,387 | )
Accrued liabilities |  |  | 888 |  |  |  | 675 |  |  |  | (1,550 | )
Deferred revenue |  |  | — |  |  |  | — |  |  |  | (21 | )
Contract liabilities and other current liabilities |  |  | (293 | ) |  |  | (1,319 | ) |  |  | (2,073 | )
Operating lease liabilities |  |  | (1,280 | ) |  |  | (762 | ) |  |  | (656 | )
Net cash used in operating activities |  |  | (38,019 | ) |  |  | (29,404 | ) |  |  | (16,075 | )
Cash flows from investing activities |  |  |  |  |  |  |  |  |  |  |  |
Sales of investment securities |  |  | 60,576 |  |  |  | — |  |  |  | — |
Purchases of investment securities |  |  | (90,158 | ) |  |  | (32,825 | ) |  |  | — |
Advance to IBEO |  |  | (4,132 | ) |  |  | — |  |  |  | — |
Proceeds on sale of property and equipment |  |  | — |  |  |  | — |  |  |  | 525 |
Purchases of property and equipment |  |  | (4,359 | ) |  |  | (2,493 | ) |  |  | (402 | )
Net cash provided by (used in) investing activities |  |  | (38,073 | ) |  |  | (35,318 | ) |  |  | 123 |
Cash flows from financing activities |  |  |  |  |  |  |  |  |  |  |  |
Principal payments under finance leases |  |  | (26 | ) |  |  | (28 | ) |  |  | (29 | )
Proceeds from long-term debt |  |  | — |  |  |  | — |  |  |  | 1,571 |
Principal payments under long-term debt |  |  | (392 | ) |  |  | (488 | ) |  |  | — |
Payments received on subscriptions receivable |  |  | — |  |  |  | 6,135 |  |  |  | — |
Proceeds from stock option exercises |  |  | 726 |  |  |  | 2,654 |  |  |  | 1,000 |
Net proceeds from issuance of common stock |  |  | 13,999 |  |  |  | 122,891 |  |  |  | 24,435 |
Net cash provided by financing activities |  |  | 14,307 |  |  |  | 131,164 |  |  |  | 26,977 |
Change in cash, cash equivalents, and restricted cash |  |  | (61,785 | ) |  |  | 66,442 |  |  |  | 11,025 |
Cash, cash equivalents, and restricted cash at beginning of period |  |  | 83,739 |  |  |  | 17,297 |  |  |  | 6,272 |
Cash, cash equivalents, and restricted cash at end of period |  | $ | 21,954 |  |  | $ | 83,739 |  |  | $ | 17,297 |
Supplemental schedule of non-cash investing and financing activities |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for subscriptions receivable |  | $ | — |  |  | $ | — |  |  | $ | 6,135 |
Property and equipment acquired under finance leases |  | $ | — |  |  | $ | — |  |  | $ | 70 |
Lease liabilities from obtaining right-of-use operating asset |  | $ | 10,184 |  |  | $ | 5,097 |  |  | $ | — |
Non-cash additions to property and equipment |  | $ | 764 |  |  | $ | 550 |  |  | $ | 116 |
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of December 31, 2022, 2021 and 2020: |  |  |  |  |  |  |  |  |  |  |  |

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Cash and cash equivalents |  | $ | 20,536 |  |  | $ | 82,647 |  |  | $ | 16,862 |
Restricted cash |  |  | 1,418 |  |  |  | 1,092 |  |  |  | 435 |
Cash, cash equivalents and restricted cash |  | $ | 21,954 |  |  | $ | 83,739 |  |  | $ | 17,297 |

The accompanying notes are an integral part of these consolidated financial statements.
31

MicroVision, Inc.
Notes to Consolidated Financial Statements
For the year ended December 31, 2022
1. THE COMPANY AND LIQUIDITY
MicroVision, Inc. is developing a lidar sensor to be used in automotive safety and autonomous driving applications. Our lidar sensor uses our pioneering laser beam scanning (LBS) technology. Our LBS technology is based on our patented expertise in systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms and software, and how those elements are packaged into a small form factor. Our lidar sensor also utilizes edge computing and machine intelligence as part of the solutions. Though automotive lidar is our priority now, we have developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
For the past few years, our strategy has been to sell AR displays or components, Interactive Displays, or Consumer Lidars to OEMs and ODMs for incorporation into their products. Currently, our sole customer is Microsoft Corporation. Our arrangement with this customer generates royalty income; however, the volume of sales and resulting royalties from that arrangement are not significant. In the recent past, we shifted our focus to increase the value of the Company by completing development of our 1st Generation LRL module to a level that would be ready to scale in the market. We believe our technology and designs for automotive lidar can be successful in the market, and our solutions will have features and performance that exceed those of competitors and will provide a sustainable strategic advantage in the market.
We have incurred significant losses since inception. We have funded our operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales and licensing activities.
Between the effectiveness of the Asset Purchase Agreement, December 1, 2022, and the closing of the acquisition, January 31, 2023, we advanced operating funds to Ibeo totaling approximately EUR 6.6 million or approximately $7.1
million to support its ongoing operations while in insolvency, of which $4.1 million was advanced prior to December 31, 2022 and the remaining amount was advanced during January 2023. These funds included costs incurred by Ibeo to reduce its headcount so that only approximately 250 employees would transfer to MicroVision upon the closing of the acquisition. The costs related to the headcount reductions will be reimbursed to MicroVision by way of deduction from the purchase price per the Asset Purchase Agreement. In addition, at closing, MicroVision paid
EUR 7.0 million or approximately $7.6 million to Ibeo and EUR 3.0 million or approximately $3.3 million to an escrow account to be available to cover properly established claims by MicroVision. We expect to make the remaining final payment of the purchase price, net of deductions, during the second quarter of 2023.
As of January 31, 2023, we had $18.5 million in cash and cash equivalents and $59.2 million in investment securities after making the payments to Ibeo as described above, but excluding the expected impact of the noted final payment that we expect to make in the second quarter. Based on our current operating plan for 2023 and beyond, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months.
2
.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from our estimates. We have identified the following areas where estimates and assumptions have been made in preparing the financial statements: revenue recognition, inventory valuation, valuation of share-based payments, income taxes, depreciable lives assessment and related disclosure of contingent assets and liabilities.
Cash and cash equivalents and fair value of financial instruments
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy, and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. We use market data, assumptions and risks we believe market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques.
3
2

Our financial instruments include cash and cash equivalents, investment securities, accounts receivable, accounts payable and accrued liabilities. The carrying value of our financial instruments approximates fair value due to their short maturities. Our cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts.
Our short-term investment securities are primarily debt securities. The Company has classified its entire investment portfolio as
available-for-sale.
Available-for-sale
securities are stated at fair value with unrealized gains and losses included in other comprehensive income (loss). Dividend and interest income are recognized when earned. Realized gains and losses are presented separately on the income statement.
Inventory
Inventory consists of raw materials, work in process and finished goods assemblies. Inventory is computed using the first-in, first-out (FIFO) method and is stated at the lower of cost and net realizable value. Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. Inventory that will not be consumed through the normal course of business during the next twelve months is classified as “other assets” on the balance sheet.
Intangible assets
Our intangible assets consist exclusively of purchased patents. The patents are amortized using the straight-line method over their estimated period of benefit, ranging from one to seventeen years. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for our intangible assets is based on the difference between the fair value of the asset and its carrying value.
Property and equipment
Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets (two to five years) using the straight-line method. Our property and equipment may include assets related to future product lines. As our production needs change, we periodically assess the remaining estimated useful life of our production equipment. If necessary, we adjust the depreciation on our production equipment to reflect the remaining estimated useful life. Leasehold improvements are depreciated over the shorter of estimated useful lives or the lease term. Costs for repairs and maintenance are charged to expense as incurred and expenditures for major improvements are capitalized at cost. Gains or losses on the disposition of assets are reflected in the income statements at the time of disposal.
Restricted cash
As of December 31, 2022 and 2021, restricted cash was in money market savings accounts and serves as collateral for irrevocable letters of credit related to our facility lease agreements. The restricted cash balance at December 31, 2022 includes $657,000 related to a letter of credit that was issued in connection with a lease agreement entered into in September 2021 for our company headquarters in Redmond, Washington. The new lease commenced on December 1, 2022, and the required balance of the letter credit periodically decreases over the term of the
120-month
lease. The restricted cash balance also includes $305,000 related to a letter of credit that was issued in connection with a lease agreement entered into in September 2021 for our general office and lab space in Redmond, Washington, and the required balance of the letter of credit periodically decreases over the term of the
120-month
lease. The restricted cash balance also includes $457,000 related to a letter of credit which is outstanding in connection with a lease agreement for our former corporate headquarters building. The balance is required over the term of the lease, which was amended to provide us access until January 31, 2023.
Leases
We determine if an arrangement is a lease at inception. On our balance sheet, our office lease is included in Operating lease
right-of-use
(ROU) asset, Current portion of operating lease liability and Operating lease liability, net of current portion. On our balance sheet, finance leases are included in Property and equipment, Current portion of finance lease obligations and Finance lease obligations, net of current portion.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For leases that do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
3
3

Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and
non-lease
components, and the determination of the discount rate included in our office lease. We review the underlying objective of each contract, the terms of the contract, and consider our current and future business conditions when making these judgments.
Revenue recognition
The following is a description of principal activities from which we generate revenue.
Revenues
are recognized when control of the promised goods or services are transferred to our customers, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We generate all of our revenue from contracts with customers.
We evaluate contracts based on the
5-step
model as stated in Topic 606 as follows: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price, and (v) recognize revenue when (or as) performance obligations are satisfied.
A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard.
The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method.
The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part.
Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time.
Product revenue
We sell our products to customers under a contract or by purchase order. We consider the sale of each individual item to be one performance obligation. The transaction price is generally either at stated product price per quantity or at a fixed amount at contract inception. Revenue is recognized under Topic 606 when the product is shipped to the customer because control passes to the customer at the point of shipment. Our product sales generally include acceptance provisions, however, because we generally can objectively determine that we have met agreed-upon customer specifications prior to shipment, control of the item passes at the time of shipment.
License and royalty revenue
We recognize revenue on upfront license fees at a point in time if the nature of the license granted is a
right-to-use
license, representing functional intellectual property with significant standalone functionality. If the nature of the license granted is a
right-to-access
license, representing symbolic intellectual property, which excludes significant standalone functionality, we recognize revenue over the period of time we have ongoing obligations under the agreement. We will recognize revenue from sales-based royalties on the basis of the quarterly reports provided by our customer as to the number of royalty-bearing products sold or otherwise distributed. In the event that reports are not received, we will estimate the number of royalty-bearing products sold by our customers.
3
4

Contract revenue
Our contract revenue in a particular period is dependent upon when we enter into a contract, the value of the contracts we have entered into, and the availability of technical resources to perform work on the contracts. We recognize contract revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) occur over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. In contracts that include significant customer acceptance provisions, we recognize revenue only upon acceptance of the deliverable(s).
We identify each performance obligation in our development contracts at contract inception. The contracts generally include product development and customization specified by the customer. In contracts with multiple performance obligations, we identify each performance obligation and evaluate whether the performance obligations are distinct within the context of the contract. Performance obligations that are not distinct at contract inception are combined.
Our development contracts are primarily
fixed-fee
contracts. If control of deliverables occurs over time, we recognize revenue on fixed fee contracts on the proportion of total cost expended (under Topic 606, the ‘input method’) to the total cost expected to complete the contract performance obligation. For contracts that require the input method for revenue recognition, the determination of the total cost expected to complete the performance obligations on fixed fee contracts involves significant judgment. We incorporate revisions to hour and cost estimates when the causal facts become known.
Cost of product revenue
Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged to us by our contract manufacturers in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with operating our manufacturing capabilities and capacity. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based on the proportion of indirect labor which supported production activities. The cost of product revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of manufacturing overhead expense and the volume of direct material purchased.
Cost of contract revenue
Cost of contract revenue includes both the direct and allocated indirect costs of performing on contracts and producing prototype units and evaluation kits based on our PicoP
®
scanning module. Direct costs include labor, materials and other costs incurred directly in producing prototype units and evaluation kits or performing on a contract. Indirect costs include labor and other costs associated with operating our research and development department and building our technical capabilities and capacity. Cost of contract revenue is determined by the level of direct and indirect costs incurred, which can fluctuate substantially from period to period.
Our overhead, which includes the costs of procuring, inspecting and storing material, and facility and depreciation costs, is allocated to inventory, cost of product revenue, cost of contract revenue, and research and development expense based on the level of effort supporting production or research and development activity.
Concentration of credit risk and major customers and suppliers
Concentration of credit risk
Financial instruments that potentially subject us to a concentration of credit risk are primarily cash equivalents and accounts receivable. We typically do not require collateral from our customers. As of December 31, 2022, our cash and cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts.
Concentration of major customers and suppliers
In 2022 one customer, Microsoft Corporation, accounted for $664,000 in revenue, representing 100% of our total revenue. In 2021, the same customer accounted for $2.5 million in revenue, representing 100% of our total revenue. In 2020, the same customer accounted for $3.0 million in revenue, representing 97% of our total revenue.
3
5

Typically, a significant concentration of our components and the products we have sold are manufactured and obtained from single or limited-source suppliers. The loss of any single or limited-source supplier, the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject us to risks and uncertainties including, but not limited to, increased cost of sales, possible loss of revenues, or significant delays in product development or product deliveries, any of which could adversely affect our financial condition and operating results.
Income taxes
Deferred tax assets and liabilities are recorded for differences between the financial statement and tax
bases
of the assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable for the period increased or decreased by the change in deferred tax assets and liabilities during the period.
Net loss per share
Basic net loss per share is calculated using the weighted-average number of common shares outstanding during the periods. Net loss per share, assuming dilution, is calculated using the weighted-average number of common shares outstanding and the dilutive effect of all potentially dilutive securities, including common stock equivalents and convertible securities. Net loss per share, assuming dilution, is equal to basic net loss per share because the effect of dilutive securities outstanding during the periods, including options and warrants computed using the treasury stock method, is anti-dilutive.
The components of basic and diluted net loss per share were as follows (in thousands, except loss per share data):

|  | Year Ended December 31, |
Numerator: |  | 2022 |  |  | 2021 |  |  | 2020 |
Net loss available for common shareholders |  | $ | (53,091 | ) |  | $ | (43,200 | ) |  | $ | (13,634 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average common shares outstanding |  |  | 165,958 |  |  |  | 160,662 |  |  |  | 139,829 |
Net loss per share - basic and diluted |  | $ | (0.32 | ) |  | $ | (0.27 | ) |  | $ | (0.10 | )

During each of the years ended December 31, 2022, 2021 and 2020, we excluded the following securities from net loss per share as the effect of including them would have been anti-dilutive. The shares shown represent the number of shares of common stock which would be issued upon conversion in the respective years shown below (in thousands):

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Options outstanding |  |  | 945 |  |  |  | 1,533 |  |  |  | 3,281 |
Nonvested restricted stock units |  |  | 8,866 |  |  |  | 2,625 |  |  |  | 1,982 |
|  |  | 9,811 |  |  |  | 4,158 |  |  |  | 5,263 |

Research and development
Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. Research and development costs are expensed as incurred. We believe that a substantial level of continuing research and development expense will be required to further develop our technology.
36

Share-based compensation
We issue share-based compensation to employees in the form of stock options and restricted stock units (RSUs), and performance stock units (PSUs). We account for the share-based awards by recognizing the fair value of share-based compensation expense on a straight-line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black-Scholes option pricing model. The fair value of RSUs and
non-executive
PSUs is determined by the closing price of our common stock on the grant date. For performance-based awards, expense is recognized when it is probable the performance criteria will be achieved. If the likelihood becomes improbable that the performance criteria will be achieved, the expense is reversed. Executive PSUs that have market-based performance criteria are valued using a binomial option pricing model using the following inputs: stock price, volatility, and risk-free interest rates. Changes in estimated inputs or using other option valuation methods may result in materially different option values and share-based compensation expense.
The following table summarizes the amount of share-based compensation expense by line item on the Statement of Operations (in thousands):

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Research and development expense |  |  | 6,933 |  |  |  | 6,125 |  |  |  | 699 |
Sales, marketing, general and administrative expense |  |  | 8,528 |  |  |  | 9,159 |  |  |  | 598 |
|  | $ | 15,461 |  |  | $ | 15,284 |  |  | $ | 1,297 |

Reclassifications
Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders’ equity or cash flows, as previously reported.
3. REVENUE RECOGNITION
The following is a description of principal activities from which we generate revenue. Revenues are recognized when control of the promised goods or services are transferred to our customers, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We generate all of our revenue from contracts with customers.
We evaluate contracts based on the
5-step
model as stated in Topic 606 as follows: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price, and (v) recognize revenue when (or as) performance obligations are satisfied.
A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard.
The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price we will use either the expected value method or the most likely amount method.
The transaction price is allocated to the separate performance obligations in the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on our part.
Revenue is recognized when (or as) the customer obtains control of the good or service/performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time.
37

Disaggregation of revenue
The following table provides information about disaggregated revenue by timing of revenue recognition, (in thousands):

|  | Year Ended December 31, 2022 |
|  |  |  |  | License and |  |  |  |  |  |  |
|  | Product |  |  | royalty |  |  | Contract |  |  |  |
|  | revenue |  |  | revenue |  |  | revenue |  |  | Total |
Timing of revenue recognition: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Products transferred at a point in time |  | $ | — |  |  | $ | 664 |  |  | $ | — |  |  | $ | 664 |
Product and services transferred over time |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | — |  |  | $ | 664 |  |  | $ | — |  |  | $ | 664 |

|  | Year Ended December 31, 2021 |
|  |  |  |  | License and |  |  |  |  |  |  |
|  | Product |  |  | royalty |  |  | Contract |  |  |  |
|  | revenue |  |  | revenue |  |  | revenue |  |  | Total |
Timing of revenue recognition: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Products transferred at a point in time |  | $ | — |  |  | $ | 2,500 |  |  | $ | — |  |  | $ | 2,500 |
Product and services transferred over time |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | — |  |  | $ | 2,500 |  |  | $ | — |  |  | $ | 2,500 |

|  | Year Ended December 31, 2020 |
|  |  |  |  | License and |  |  |  |  |  |  |
|  | Product |  |  | royalty |  |  | Contract |  |  |  |
|  | revenue |  |  | revenue |  |  | revenue |  |  | Total |
Timing of revenue recognition: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Products transferred at a point in time |  | $ | 1,347 |  |  | $ | 1,718 |  |  | $ | 4 |  |  | $ | 3,069 |
Product and services transferred over time |  |  | — |  |  |  | — |  |  |  | 21 |  |  |  | 21 |
Total |  | $ | 1,347 |  |  | $ | 1,718 |  |  | $ | 25 |  |  | $ | 3,090 |

Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands):

|  | December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Accounts receivable, net |  | $ | — |  |  | $ | — |  |  | $ | — |
Accrued liabilities |  |  | — |  |  |  | — |  |  |  | — |
Deferred revenue |  |  | — |  |  |  | — |  |  |  | — |
Contract liabilities |  |  | 4,601 |  |  |  | 5,265 |  |  |  | 7,765 |

Under Topic 606, our rights to consideration are presented separately depending on whether those rights are conditional or unconditional. We present our unconditional rights to consideration as “accounts receivable” in our Balance Sheet.
Significant changes in the contract assets and the contract liabilities balances during the period are as follows (in thousands, except percentages):
3
8

|  | December 31, |  |  | December 31, |  |  |  |  |  |  |
|  | 2022 |  |  | 2021 |  |  | $Change |  |  | % Change |
Contract assets |  | $ | — |  |  | $ | — |  |  | $ | — |  |  |  | — |
Contract liabilities |  |  | (4,601 | ) |  |  | (5,265 | ) |  |  | 664 |  |  |  | 12.6 |
Net contract assets (liabilities) |  | $ | (4,601 | ) |  | $ | (5,265 | ) |  | $ | 664 |  |  |  | 12.6 |

In April 2017, we signed a contract with Microsoft Corporation to develop an LBS display system. Under the agreement, we received an upfront payment of $10.0 million. As of December 31, 2022, we had applied $5.4 million against the contract liability. During the year ended December 31, 2022, we applied $664,000 against the contract liability with this customer.
Contract acquisition costs
We are required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed. We currently do not pay any commissions upon the signing of a contract; therefore, no commission cost has been incurred as of December 31, 2022.
Transaction price allocated to the remaining performance obligations
The $10.0 million upfront payment received from our customer as noted above was being recognized as revenue as component sales were transferred to the customer. Under the new arrangement reached in March 2020, the royalties we expect to earn will be applied against the remaining prepayment. Because we do not have information on projected future shipments by our customer, we are not able to estimate the timing of revenue recognition related to the remaining performance obligations. The $4.6 million contract liability is classified as a current liability on our balance sheet. It is likely that recognition of revenue may extend beyond the next twelve months.
4. INVESTMENT SECURITIES,
AVAILABLE-FOR-SALE
AND FAIR VALUE MEASUREMENTS
Our investment securities,
available-for-sale
are comprised of corporate debt securities. The principal markets for the debt securities are dealer markets which have a high level of price transparency. The market participants for debt securities are typically large money center banks and regional banks, brokers, dealers, pension funds, and other entities with debt investment portfolios.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. We use market data, assumptions and risks we believe market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. The hierarchy is summarized below.
Level 1 – Quoted prices in active markets for identical assets and liabilities at the measurement date that the reporting entity has the ability to access.
Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 – Unobservable inputs for which there is little or no market data, which requires us to develop our own assumptions, which are significant to the measurement of the fair values.
The valuation inputs hierarchy classification for assets measured at fair value on a recurring basis are summarized below as of December 31, 2022 and 2021 (in thousands). These tables do not include cash held in our money market savings accounts.
39

As of December 31, 2022 |  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | — |  |  | $ | 15,500 |  |  | $ | — |  |  | $ | 15,500 |
U.S. Treasury securities |  |  | — |  |  |  | 46,673 |  |  |  | — |  |  |  | 46,673 |
|  | $ | — |  |  | $ | 62,173 |  |  | $ | — |  |  | $ | 62,173 |
As of December 31, 2021 |  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | — |  |  | $ | 32,720 |  |  | $ | — |  |  | $ | 32,720 |
|  | $ | — |  |  | $ | 32,720 |  |  | $ | — |  |  | $ | 32,720 |

Our short-term investments are summarized below as of December 31, 2022 and 2021 (in thousands).

|  |  |  |  |  |  |  |  |  |  | Investment |
|  | Cost/ |  |  | Gross |  |  | Gross |  |  | Securities, |
|  | Amortized |  |  | Unrealized |  |  | Unrealized |  |  | Available- |
|  | Cost |  |  | Gains |  |  | Losses |  |  | For-Sale |
As of December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | 15,538 |  |  | $ | — |  |  | $ | (38 | ) |  | $ | 15,500 |
U.S. Treasury securities |  |  | 46,762 |  |  |  | 2 |  |  |  | (91 | ) |  |  | 46,673 |
|  | $ | 62,300 |  |  | $ | 2 |  |  | $ | (129 | ) |  | $ | 62,173 |
As of December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | 32,739 |  |  | $ | 3 |  |  | $ | (22 | ) |  | $ | 32,720 |
|  | $ | 32,739 |  |  | $ | 3 |  |  | $ | (22 | ) |  | $ | 32,720 |

The maturities of the investment securities
available-for-sale
as of December 31, 2022 and 2021 are shown below (in thousands):

|  | Amortized Cost |  |  | Gross Unrealized Gains |  |  | Gross Unrealized Losses |  |  | Estimated Fair Value |
As of December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less than one year |  | $ | 62,300 |  |  | $ | 2 |  |  | $ | (129 | ) |  | $ | 62,173 |
|  | $ | 62,300 |  |  |  |  |  |  |  |  |  |  | $ | 62,173 |
As of December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less than one year |  | $ | 32,739 |  |  | $ | 3 |  |  | $ | (22 | ) |  | $ | 32,720 |
|  | $ | 32,739 |  |  |  |  |  |  |  |  |  |  | $ | 32,720 |

The following table summarizes investments that have been in a continuous unrealized loss position for less than 12 months and those that have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021 (in thousands):
40

|  | Less than Twelve Months |  |  | Twelve Months or Greater |  |  | Total |
|  |  |  |  | Gross |  |  |  |  |  | Gross |  |  |  |  |  | Gross |
|  | Fair |  |  | Unrealized |  |  | Fair |  |  | Unrealized |  |  | Fair |  |  | Unrealized |
|  | Value |  |  | Losses |  |  | Value |  |  | Losses |  |  | Value |  |  | Losses |
As of December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | 12,295 |  |  | $ | (38 | ) |  | $ | — |  |  | $ | — |  |  |  | 12,295 |  |  |  | (38 | )
U.S. Treasury securities |  |  | 34,530 |  |  |  | (91 | ) |  |  | — |  |  |  | — |  |  |  | 34,530 |  |  |  | (91 | )
|  | $ | 46,825 |  |  | $ | (129 | ) |  | $ | — |  |  | $ | — |  |  | $ | 46,825 |  |  | $ | (129 | )
As of December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  | $ | 27,195 |  |  | $ | (22 | ) |  | $ | — |  |  | $ | — |  |  |  | 27,195 |  |  |  | (22 | )
|  | $ | 27,195 |  |  | $ | (22 | ) |  | $ | — |  |  | $ | — |  |  | $ | 27,195 |  |  | $ | (22 | )

5. INVENTORY
Inventory consists of the following (in thousands):

|  | December 31, |
|  | 2022 |  |  | 2021 |
Raw materials |  | $ | 1,556 |  |  | $ | 1,780 |
Work in process |  |  | 305 |  |  |  | — |
|  | $ | 1,861 |  |  | $ | 1,780 |

We recorded inventory write-downs of $87,000 in 2022, $48,000 in 2021 and $168,000 in 2020.
6. ACCRUED LIABILITIES
Accrued liabilities consists of the following (in thousands):

|  | December 31, |
|  | 2022 |  |  | 2021 |
Bonuses |  | $ | 537 |  |  | $ | 43 |
Payroll and payroll taxes |  |  | 766 |  |  |  | 601 |
Accrued professional fees |  |  | 378 |  |  |  | 89 |
Liabilities to suppliers |  |  | 130 |  |  |  | 263 |
Other |  |  | 247 |  |  |  | 174 |
|  | $ | 2,058 |  |  | $ | 1,170 |

7. PROPERTY AND EQUIPMENT
Property and equipment consists of the following (in thousands):

|  | December 31, |
|  | 2022 |  |  | 2021 |
Production equipment |  | $ | 6,140 |  |  | $ | 8,224 |
Leasehold improvements |  |  | 3,789 |  |  |  | 913 |
Computer hardware and software/lab equipment |  |  | 10,515 |  |  |  | 7,230 |
Office furniture and equipment |  |  | 1,804 |  |  |  | 1,372 |
|  |  | 22,248 |  |  |  | 17,739 |
Less: Accumulated depreciation |  |  | (15,418 | ) |  |  | (14,713 | )
|  | $ | 6,830 |  |  | $ | 3,026 |

Depreciation expense was $705,000 in 2022, $902,000 in 2021 and $442,000 in 2020.
4
1

8. INTANGIBLE ASSETS
Our intangible assets consist exclusively of technology-based purchased patents. The gross book value of our intangible assets was $951,000 in the years ended December 31, 2022 and 2021, respectively. Amortization expense was $40,000 in 2022, $49,000 in 2021 and $57,000 in 2020. The following table outlines our estimated future amortization expense related to intangible assets held at December 31, 2022 (in thousands):

Years Ended December 31, |  | Amount |
2023 |  |  | 32 |
2024 |  |  | 22 |
2025 |  |  | 14 |
2026 |  |  | 7 |
|  |  | 75 |

9. COMMON STOCK
In June 2021, we entered into a $140.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we are able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $140.0 million through Craig-Hallum. In 2021, we had issued 4.0 million shares of our common stock for net proceeds of $67.8 million under this ATM agreement. In 2022, we issued 4.3 million shares of our common stock for net proceeds of $14.0 million under this ATM agreement. In January 2023, we issued 5.0 million shares of our common stock for net proceeds of $12.5 million under the agreement. As of February 28, 2023, we have approximately $43.5
million available under this ATM agreement.
In February 2021, we entered into a $50.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to $50.0 million through Craig-Hallum. We issued 2.5 million shares of our common stock for net proceeds of $48.8 million under this ATM agreement. No further shares are available for sales under this agreement.
In December 2020, we entered into a $13.0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, from time to time, at our discretion to offer and sell shares of our common stock having an aggregate value of up to $13.0 million through Craig-Hallum. As of December 31, 2020, we had issued 1.0 million shares for net proceeds of $6.1 million that was received in January 2021. The $6.1 million was classified as subscriptions receivable on our December 31, 2020 balance sheet and is not included in the cash balance as of December 31, 2020. In January 2021, we issued 1.1 million shares of our common stock for net proceeds of $6.6 million under the agreement. In total, we issued 2.1 million shares of our common stock for net proceeds of $12.7 million under this ATM agreement. No further shares are available for sales under this agreement.
10. SHARE-BASED COMPENSATION
We use the straight-line attribution method to allocate the fair value of share-based compensation awards over the requisite service period for each award. The valuation of and accounting for share-based awards includes a number of complex and subjective estimates. These estimates include, but are not limited to, the future volatility of our stock price, future stock option exercise behaviors, estimated employee turnover, and award forfeiture rates.
Description of Incentive Plan
Our 2022 Incentive Plan has 20.0 million shares authorized, which includes 3.5 million shares not issued pursuant to any awards granted under the 2020 Incentive Plan. There were 12.7 million shares available for awards as of December 31, 2022.
Options Valuation Methodology and Assumptions
We use the Black-Scholes option valuation model to determine the fair value of options granted and use the closing price of our common stock as the fair market value of our stock on that date.
We consider historical stock price volatilities, volatilities of similar companies and other factors in determining estimates of future volatilities.
We use historical lives, including post-termination exercise behavior, as the basis for estimating expected lives.
Risk-free rates are based on the U.S. Treasury Yield Curve, as published by the U.S. Treasury.
4
2

The following table summarizes the weighted-average valuation assumptions and weighted-average grant date fair value of options granted during the periods shown below:

|  | Year Ended December 31, |
Assumptions (weighted-average) |  | 2022 |  |  | 2021 |  |  | 2020 |
Volatility |  |  | — |  |  |  | 120 | % |  |  | 111 | %
Expected term (in years) |  |  | — |  |  |  | 4.0 |  |  |  | 4.0 |
Risk-free rate |  |  | — |  |  |  | 0.9 | % |  |  | 0.3 | %
Expected dividends |  |  | — |  |  |  | 0.0 | % |  |  | 0.0 | %
Pre-vest forfeiture rate |  |  | — |  |  |  | 8.5 | % |  |  | 8.5 | %
Grant date fair value of options granted |  | $ | — |  |  | $ | 11.72 |  |  | $ | 1.20 |

Options Activity and Positions
The following table summarizes activity and positions with respect to options for the periods shown below (in thousands):

|  |  |  |  |  |  |  | Weighted-average |  |  |  |
|  |  |  |  |  |  |  | remaining |  |  | Aggregate |
|  |  |  |  | Weighted-average |  |  | contractual |  |  | intrinsic |
Options |  | Shares |  |  | exercise price |  |  | term (in years) |  |  | value |
Outstanding as of December 31, 2019 |  |  | 5,104 |  |  |  | 1.66 |  |  |  | 7.4 |  |  | $ | 122 |
Granted |  |  | 68 |  |  |  | 1.60 |  |  |  |  |  |  |  |  |
Exercised |  |  | (693 | ) |  |  | 1.44 |  |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (1,198 | ) |  |  | 2.20 |  |  |  |  |  |  |  |  |
Outstanding as of December 31, 2020 |  |  | 3,281 |  |  |  | 1.51 |  |  |  | 6.6 |  |  | $ | 12,784 |
Granted |  |  | 8 |  |  |  | 14.04 |  |  |  |  |  |  |  |  |
Exercised |  |  | (1,519 | ) |  |  | 1.75 |  |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (237 | ) |  |  | 1.23 |  |  |  |  |  |  |  |  |
Outstanding as of December 31, 2021 |  |  | 1,533 |  |  |  | 1.37 |  |  |  | 5.6 |  |  | $ | 5,645 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (525 | ) |  |  | 1.38 |  |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (63 | ) |  |  | 3.00 |  |  |  |  |  |  |  |  |
Outstanding as of December 31, 2022 |  |  | 945 |  |  | $ | 1.26 |  |  |  | 5.7 |  |  | $ | 1,137 |
Vested and expected to vest as of December 31, 2022 |  |  | 945 |  |  | $ | 1.26 |  |  |  | 5.7 |  |  | $ | 1,136 |
Exercisable as of December 31, 2022 |  |  | 941 |  |  | $ | 1.26 |  |  |  | 5.7 |  |  | $ | 1,129 |

The total grant date fair value of options vested during the years ended December 31, 2022, 2021 and 2020 was $115,000, $508,000 and $604,000, respectively. As of December 31, 2022, our unrecognized share-based compensation was $1,000 related to options, which we plan to expense over the next 1.2 years.
Restricted stock activity and positions
The following table summarizes activity and positions with respect to RSUs and PSUs for the three years ended December 31, 2022 (in thousands):
4
3

|  |  |  |  | Weighted-average |
|  | Shares |  |  | price |
Unvested as of December 31, 2019 |  |  | 1,215 |  |  |  | 0.40 |
Granted |  |  | 1,462 |  |  |  | 1.08 |
Vested |  |  | (219 | ) |  |  | 0.88 |
Forfeited |  |  | (475 | ) |  |  | 0.77 |
Unvested as of December 31, 2020 |  |  | 1,983 |  |  |  | 0.76 |
Granted |  |  | 4,179 |  |  |  | 12.92 |
Vested |  |  | (2,380 | ) |  |  | 3.11 |
Forfeited |  |  | (1,157 | ) |  |  | 11.97 |
Unvested as of December 31, 2021 |  |  | 2,625 |  |  |  | 13.05 |
Granted |  |  | 9,180 |  |  |  | 2.46 |
Vested |  |  | (1,391 | ) |  |  | 9.16 |
Forfeited |  |  | (1,548 | ) |  |  | 6.42 |
Unvested as of December 31, 2022 |  |  | 8,866 |  |  | $ | 3.85 |

In June 2022, we issued 6.0 million PSUs to our executive officers. The PSUs are subject to the achievement of performance goals and time-based vesting. The PSUs will become eligible to vest if the closing price of our common stock reaches or exceeds specified price thresholds for at least 20 consecutive trading days during the performance period through December 31, 2025. If the performance goals are met, the portion of the PSUs deemed earned will become subject to time-based vesting in equal quarterly installments over two years starting from the date on which the goal is achieved. These PSUs were valued using a Monte Carlo simulation model using the following inputs: stock price, volatility, and risk-free interest rates.
In 2022, we issued 2.4 million PSUs to
non-executive
employees subject to the achievement of development goals. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest quarterly over two years from the achievement of established performance criteria. We canceled 426,000 PSUs in the fourth quarter of 2022 and
re-issued
106,000 PSUs in the first quarter of 2023 due to partial achievement of internal performance milestones.
In 2022, we issued 570,000 time-based RSUs to
non-executive
employees for promotion, retention, and new hire grants. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest over three or four years from the date of grant.
In 2021, an equity award was granted to the Chief Executive Officer in the form of 1.2 million restricted stock units. These shares were valued based on the closing price of our common stock on the dates of grant. On the date of grant, 300,000 shares vested immediately, 300,000 vested in April 2022 and subsequent grants of 300,000 RSUs will be made on an annual basis in each of April 2023 and April 2024.
In 2021, we issued 1.5 million shares of performance stock units to
non-executive
employees. These shares were valued based on the closing price of our common stock on the dates of grant. The shares vest
one-eighth
upon achievement of performance milestones with the remainder vesting quarterly over the following seven quarters. In 2021, 1.1 million of the performance stock units were canceled because of modifications to or failure to achieve performance milestones.
In 2021, we issued 1.1 million RSUs to
non-executive
employees for promotion, retention and new hire grants. These shares were valued based on the closing price of our common stock on the dates of grant. These shares vest annually over one to four years from the date of grant.
As of December 31, 2022, our unrecognized share-based compensation related to RSUs was $13.1 million, which we plan to expense over the next 1.6 years, our unrecognized share-based compensation related to executive PSUs was $7.9 million, which we plan to expense over the next 2.7 years, and our unrecognized share-based compensation related to the
non-executive
PSUs was $2.0 million, which we plan to expense over the next 1.0 year.
4
4

11. LEASES
We lease our office space and certain equipment under finance and operating leases. Our leases have remaining lease terms of one month to ten years. Our office lease agreement includes both lease and
non-lease
components, which are accounted for separately. Our finance leases contain options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless we are reasonably certain to exercise the purchase option.
In September 2021, we entered into an office lease with Redmond East Office Park LLC, a Washington limited liability company, pursuant to which we will lease approximately 16,681 square feet of space located in Redmond, Washington that we will use primarily for general office space and product testing. The lease provides for an initial term of 128 months that commenced November 1, 2021. Pursuant to the lease, annual base rent will be approximately $
500,000
for the first year and is subject to annual increases of
3.0
%. In addition to base rent, we will pay additional rent comprised of our proportionate share of any operating expenses, real estate taxes, and management fees. We have the option to extend the term for one
ten-year
renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $
6.4
million.
In September 2021, we entered into a second office lease with Redmond East Office Park LLC, pursuant to which we will lease approximately 36,062 square feet of space located in Redmond, Washington that we will use primarily for general office and lab space. The lease provides for an initial term of 120 months and commenced on December 1, 2022. Pursuant to the lease, annual base rent will be approximately $
1.1
million for the first year and is subject to annual increases of 3.0%. In addition to base rent, we will pay additional rent comprised of our proportionate share of any operating expenses, real estate taxes, and management fees. We have the option to extend the term for one
ten-year
renewal period, provided that the rent would be subject to market adjustment at the beginning of the renewal term. The total minimum lease payments related to this lease is $
13.0
million. The delivery date of the new space was September 1, 2022 to allow for the build out of tenant improvements before the commencement date. During the quarter ended September 30, 2022, we recorded a
right-of-use
asset in the amount of $9.3 million on our balance sheet.
In connection with the effectiveness of the second lease with Redmond East Office Park, we amended our current office lease and will have access until January 31, 2023 to coincide with our move into the new 36,062 square feet of space.
In April 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,533 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced May 1, 2022. Pursuant to the lease, annual base rent is approximately $
76,000
per year. The total minimum lease payments related to this lease is approximately $
380,000
.
In September 2022, we entered into an office lease with Universal-Investment-Gesellschaft mbH, a German investment company, pursuant to which we lease approximately 3,810 square feet of space located in Nuremberg, Germany that we use primarily for general office space for business development activities. The lease provides for a term of 60 months that commenced November 15, 2022. Pursuant to the lease, annual base rent is approximately $92,000 per year. The total minimum lease payments related to this lease is approximately $461,000.
The components of lease expense were as follows:

|  | Year Ended December 31, |
(in thousands) |  | 2022 |  |  | 2021 |  |  | 2020 |
Operating lease expense |  | $ | 1,501 |  |  | $ | 513 |  |  | $ | 464 |
Finance lease expense: |  |  |  |  |  |  |  |  |  |  |  |
Amortization of leased assets |  |  | 26 |  |  |  | 30 |  |  |  | 26 |
Interest on lease liabilities |  |  | 2 |  |  |  | 3 |  |  |  | 3 |
Total finance lease expense |  |  | 28 |  |  |  | 33 |  |  |  | 29 |
Total lease expense |  | $ | 1,529 |  |  | $ | 546 |  |  | $ | 493 |

4
5

Supplemental cash flow information related to leases was as follows:

|  | Year Ended December 31, |
(in thousands) |  | 2022 |  |  | 2021 |  |  | 2020 |
Cash paid for amounts included in measurement of lease liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Operating cash flows from operating leases |  | $ | 1,280 |  |  | $ | 762 |  |  | $ | 656 |
Operating cash flows from finance leases |  |  | 2 |  |  |  | 3 |  |  |  | 3 |
Financing cash flows from finance leases |  |  | 26 |  |  |  | 28 |  |  |  | 29 |
Right-of-use assets obtained in exchange for new lease obligations: |  |  |  |  |  |  |  |  |  |  |  |
Operating leases |  | $ | 10,184 |  |  | $ | 5,322 |  |  | $ | — |

Supplemental balance sheet information related to leases was as follows:

|  | December 31, |
(in thousands) |  | 2022 |  |  | 2021 |
Operating leases |  |  |  |  |  |  |  |
Operating lease right-of-use assets |  | $ | 14,579 |  |  | $ | 5,577 |
Current portion of operating lease liability |  |  | 1,846 |  |  |  | 849 |
Operating lease liability, net of current portion |  |  | 13,829 |  |  |  | 4,983 |
Total operating lease liabilities |  | $ | 15,675 |  |  | $ | 5,832 |
Finance leases |  |  |  |  |  |  |  |
Property and equipment, at cost |  | $ | 112 |  |  | $ | 112 |
Accumulated depreciation |  |  | (80 | ) |  |  | (56 | )
Property and equipment, net |  | $ | 32 |  |  | $ | 56 |
Current portion of finance lease obligations |  | $ | 21 |  |  | $ | 21 |
Finance lease obligations, net of current portion |  |  | — |  |  |  | 26 |
Total finance lease liabilities |  | $ | 21 |  |  | $ | 47 |
Weighted Average Remaining Lease Term |  |  |  |  |  |  |  |
Operating leases |  |  | 13.1 years |  |  |  | 9.5 years |
Finance leases |  |  | 0.5 years |  |  |  | 1.2 years |
Weighted Average Discount Rate |  |  |  |  |  |  |  |
Operating leases |  |  | 9.0 | % |  |  | 2.5 | %
Finance leases |  |  | 6.3 | % |  |  | 6.3 | %

46

As of December 31, 2022, maturities of lease liabilities were as follows:

(in thousands) |  | Operating |  |  | Finance |
Years Ended December 31, |  | leases |  |  | leases |
2023 |  |  | 1,904 |  |  |  | 22 |
2024 |  |  | 1,896 |  |  |  | — |
2025 |  |  | 1,947 |  |  |  | — |
2026 |  |  | 2,000 |  |  |  | — |
Thereafter |  |  | 11,642 |  |  |  | — |
Total minimum lease payments |  |  | 19,389 |  |  |  | 22 |
Less: amount representing interest |  |  | (3,714 | ) |  |  | (1 | )
Present value of lease liabilities |  | $ | 15,675 |  |  | $ | 21 |

12. COMMITMENTS AND CONTINGENCIES
Litigation
We are subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently party to any legal proceedings that management believes are reasonably possible to have a material adverse effect on our financial position, results of operations or cash flows.
13. INCOME TAXES
No provision for income taxes has been recorded for 2022, 2021 and 2020 due to the valuation allowances placed against the net operating losses and deferred tax assets arising during such periods. A valuation allowance has been recorded for all deferred tax assets. Based on our history of losses since inception, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets.
The effective tax rate of our provision (benefit) for income taxes differs from the Federal statutory rate as follows:

|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Statutory rate |  |  | 21.0 | % |  |  | 21.0 | % |  |  | 21.0 | %
Compensation related |  |  | (0.5 | )% |  |  | (8.2 | )% |  |  | 0.0 | %
Share-based compensation |  |  | (2.2 | )% |  |  | 25.1 | % |  |  | 0.0 | %
Net operating loss expiration |  |  | (9.0 | )% |  |  | (16.2 | )% |  |  | (47.5 | )%
Tax credits |  |  | 1.5 | % |  |  | 1.4 | % |  |  | 2.2 | %
Change in valuation allowance |  |  | (10.8 | )% |  |  | (23.1 | )% |  |  | 24.3 | %
Total |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %

47

Deferred tax assets are summarized as follows (in thousands):

|  | December 31, |
|  | 2022 |  |  | 2021 |
Deferred tax assets |  |  |  |  |  |  |  |
Reserves |  | $ | 651 |  |  | $ | 634 |
Net operating loss carryforwards |  |  | 92,469 |  |  |  | 90,593 |
R&D credit carryforwards |  |  | 9,628 |  |  |  | 8,984 |
Depreciation/amortization deferred |  |  | 19,787 |  |  |  | 17,417 |
Operating lease liabilities |  |  | 3,292 |  |  |  | 1,222 |
Other |  |  | 7,360 |  |  |  | 6,701 |
Total deferred tax assets |  |  | 133,187 |  |  |  | 125,551 |
Deferred tax liabilities: |  |  |  |  |  |  |  |
Operating lease right-of-use assets |  |  | (3,062 | ) |  |  | (1,171 | )
Total deferred tax liabilities |  |  | (3,062 | ) |  |  | (1,171 | )
Net valuation allowances |  |  | (130,125 | ) |  |  | (124,380 | )
Deferred tax assets |  | $ | — |  |  | $ | — |

At December 31, 2022, we have net operating loss carryforwards of approximately $
440.3
million for federal income tax reporting purposes. In addition, we have research and development tax credits of $
9.6
million. During 2022, $
22.0
million federal net operating losses and $
171,000
general business credits expired unused. A majority of the net operating loss carryforwards and research and development credits available to offset future taxable income, if any, will expire in varying amounts from
2023
to
2042
, if not previously used.
Certain net operating losses arise from the deductibility for tax purposes of compensation under nonqualified stock options equal to the difference between the fair value of the stock on the date of exercise and the exercise price of the options. For financial reporting purposes, the tax effect of this deduction, when recognized, is accounted for as an income tax benefit.
In certain circumstances, as specified in the Internal Revenue Code, a 50% or more ownership change by certain combinations of our shareholders during any three year period would result in limitations on our ability to use a portion of our net operating loss carryforwards.
We had no unrecognized tax benefits at December 31, 2022 or 2021.
We recognize interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022, 2021 and 2020 we recognized no interest or penalties.
We file income tax returns in the U.S. federal jurisdiction and Oregon. Due to our operating loss and credit carryforwards, the U.S. federal statute of limitations remains open for 1998 and onward.
14. RETIREMENT SAVINGS PLAN
We have a retirement savings plan that qualifies under Internal Revenue Code Section 401(k). The plan covers all qualified employees. Contributions to the plan are made at the discretion of our Board of Directors. During the years ended December 31, 2022, 2021 and 2020 we contributed $411,000, $259,000 and $213,000 to the plan, respectively.
48

15. QUARTERLY FINANCIAL INFORMATION (Unaudited)
The following table summarizes our unaudited quarterly financial information for the periods shown below (in thousands, except per share data):

|  | Fiscal Year 2022 |
|  | December 31, |  |  | September 30, |  |  | June 30, |  |  | March 31, |
Revenue |  | $ | — |  |  | $ | — |  |  | $ | 314 |  |  | $ | 350 |
Gross profit |  |  | (33 | ) |  |  | (45 | ) |  |  | 296 |  |  |  | 346 |
Net loss |  |  | (13,475 | ) |  |  | (12,851 | ) |  |  | (13,597 | ) |  |  | (13,168 | )
Net loss per share, basic and diluted |  |  | (0.08 | ) |  |  | (0.08 | ) |  |  | (0.08 | ) |  |  | (0.08 | )

|  | Fiscal Year 2021 |
|  | December 31, |  |  | September 30, |  |  | June 30, |  |  | March 31, |
Revenue |  | $ | 557 |  |  | $ | 718 |  |  | $ | 746 |  |  | $ | 479 |
Gross profit |  |  | 509 |  |  |  | 728 |  |  |  | 777 |  |  |  | 484 |
Net loss |  |  | (12,625 | ) |  |  | (9,382 | ) |  |  | (14,962 | ) |  |  | (6,231 | )
Net loss per share, basic and diluted |  |  | (0.08 | ) |  |  | (0.06 | ) |  |  | (0.09 | ) |  |  | (0.04 | )

|  | Fiscal Year 2020 |
|  | December 31, |  |  | September 30, |  |  | June 30, |  |  | March 31, |
Revenue |  | $ | 395 |  |  | $ | 639 |  |  | $ | 587 |  |  | $ | 1,469 |
Gross profit |  |  | 395 |  |  |  | 639 |  |  |  | 588 |  |  |  | 70 |
Net loss |  |  | (3,570 | ) |  |  | (2,826 | ) |  |  | (2,304 | ) |  |  | (4,934 | )
Net loss per share, basic and diluted |  |  | (0.02 | ) |  |  | (0.02 | ) |  |  | (0.02 | ) |  |  | (0.04 | )

16. SUBSEQUENT EVENT
On December 1, 2022, MicroVision GmbH, a company organized under the laws of The Federal Republic of Germany and wholly owned subsidiary of MicroVision, Inc., entered into an Asset Purchase Agreement with Ibeo Automotive Systems GmbH, a company organized under the laws of The Federal Republic of Germany, pursuant to which MicroVision has agreed to acquire from Ibeo certain assets related to Ibeo’s lidar sensor business. Ibeo Automotive Systems GmbH also operates in the ADAS industry providing Lidar based solutions to its customers.
Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the purchase price MicroVision agreed to pay to Ibeo is EUR 15.0 million or approximately $16.1 million, subject to potential reduction on the terms set forth in the Asset Purchase Agreement. MicroVision has also advanced operating funds to Ibeo during the
pre-Closing
period on the terms and subject to the conditions set forth in the Asset Purchase Agreement.
On January 31, 2023, the acquisition of certain assets of Ibeo was completed. Through the closing date, Microvision has advanced operating funds to Ibeo totaling EUR 6.6 million or approximately $7.1
million for its ongoing operations, of which $4.1 million was advanced prior to December 31, 2022 and the remaining amount was advanced during January 2023. These operating funds also included costs related to headcount reductions carried out by Ibeo management, decreasing the number of employees to transfer in connection with the acquisition to approximately 250 employees. These headcount reduction costs will be reimbursed to MicroVision by way of deduction from the purchase price in accordance with the Asset Purchase Agreement. In addition, upon closing, MicroVision has made payments of
EUR 7.0 million or approximately $7.6 million to Ibeo and EUR 3.0 million or approximately $3.3 million to an escrow account towards the purchase price. We expect to make the remaining final payment in Q2 2023 net of all such costs that will be reimbursed to MicroVision per the Asset Purchase Agreement.
49

##### Table of Contents

ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

There have been no changes in or disagreements with accountants on accounting or financial disclosure matters during our fiscal years ended December 31, 2022, 2021 and 2020.

ITEM 9A. | CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer (CEO) and the Chief Financial Officer (CFO) evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e)) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of this Form 10-K. Based upon that evaluation, our CEO and CFO concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

(b) Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation under the framework in Internal Control — Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December 31, 2022.

(c) Limitations on the Effectiveness of Controls. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

(d) Changes in Internal Control Over Financial Reporting. Except for the changes in connection with our implementation of the remediation plan discussed above, there were no other changes in our internal control over financial reporting during the quarter ended December 31, 2022 which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

50

##### Table of Contents

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of

MicroVision, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Microvision Inc.’s (the “Company”) internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022 based on criteria established in Internal Control – Integrated Framework (2013) issued by COSO.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of Microvision Inc. as of December 31, 2022 and December 31, 2021, the related consolidated statements of operations, comprehensive loss, changes in shareholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and schedule (collectively referred to as the “consolidated financial statements”) and our report dated March 1, 2023 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting included in Item 9A. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Moss Adams LLP

Seattle, Washington

March 1, 2023

51

##### Table of Contents

ITEM 9B. | OTHER INFORMATION

None.

ITEM 9C. | DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

PART III.

ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information regarding executive officers is included in Part I of this Annual Report on Form 10-K in Item 4A. The information required by this Item 10 of Form 10-K and not provided in Item 4A will be included under the caption “Proposal one - Election of Directors” and “Board of Directors & Governance Matters” in our 2023 Proxy Statement and is incorporated herein by reference. Our 2023 Proxy Statement will be filed with the SEC prior to our 2023 Annual Meeting of Shareholders.

ITEM 11. | EXECUTIVE COMPENSATION

The information required by this Item 11 of Form 10-K will be included under the captions “Executive Compensation,” “Compensation Committee Interlocks and Insider Participation,” and “Director Compensation for 2022” in our 2023 Proxy Statement and are incorporated herein by reference.

ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information as of December 31, 2022, regarding equity compensation plans approved and not approved by shareholders is summarized in the following table (in thousands, except per share data):

|  | Equity Compensation Plan Information |
|  | Number of |  |  |  |  |  | Number of securities |
|  | securities to be |  |  | Weighted- |  |  | remaining available for |
|  | issued upon |  |  | average exercise |  |  | further issuance under |
|  | exercise of |  |  | price of |  |  | equity compensation |
|  | outstanding |  |  | outstanding |  |  | plans (excluding |
|  | options, warrants |  |  | options, warrants |  |  | securities reflected in |
|  | and rights |  |  | and rights |  |  | column (a)) |
Plan Category |  | (a) |  |  | (b) |  |  | (c) |
Equity compensation plans approved by shareholders |  |  |  |  |  |  |  |  |  |  | 12,732 |
Options to purchase common stock |  |  | 945 |  |  | $ | 1.26 |  |  |  |  |
Restricted stock units and performance stock units |  |  | 8,866 |  |  |  | — |  |  |  |  |
Equity compensation plans not approved by shareholders |  |  | — |  |  |  | — |  |  |  | — |
Total |  |  | 9,811 |  |  |  |  |  |  |  | 12,732 |

The other information required by this Item 12 of Form 10-K will be included under the caption “Information about MicroVision Common Stock” in our 2023 Proxy Statement and is incorporated herein by reference.

52

##### Table of Contents

ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The information required by this Item 13 of Form
10-K
will be included under the captions “Certain Relationships and Related Transactions” and “Board of Directors & Governance Matters” in our 2023 Proxy Statement and are incorporated herein by reference.

ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this Item 14 of Form
10-K
will be included under the caption “Independent Registered Public Accounting Firm” in our 2023 Proxy Statement and is incorporated herein by reference.
PART IV.

ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(A) Documents filed as part of this Annual Report on Form
10-K:
1. Consolidated Financial Statements

| • |  | Report of Independent Registered Public Accounting Firm

| • |  | Consolidated Balance Sheets as of December 31, 2022 and 2021

| • |  | Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020

| • |  | Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020

| • |  | Consolidated Statements of Shareholders’ Equity (Deficit) for the years ended December 31, 2022, 2021 and 2020

| • |  | Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020

| • |  | Notes to Consolidated Financial Statements

2. Financial Statement Schedules
Schedule II
MicroVision, Inc.
Valuation and Qualifying Accounts and Reserves Schedule
(In thousands)

|  |  |  |  | Additions |  |  |  |  |  |  |
|  | Balance at |  |  | Charges |  |  | Charges |  |  |  |  |  | Balance |
|  | beginning of |  |  | to costs and |  |  | to other |  |  |  |  |  | at end of |
Year Ended December 31, |  | fiscal period |  |  | expenses |  |  | accounts |  |  | Deductions |  |  | fiscal period |
2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tax valuation allowance |  | $ | 117,725 |  |  | $ | — |  |  | $ | — |  |  | $ | (3,318 | ) |  | $ | 114,407 |
2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tax valuation allowance |  | $ | 114,407 |  |  | $ | 9,973 |  |  | $ | — |  |  | $ | — |  |  | $ | 124,380 |
2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tax valuation allowance |  | $ | 124,380 |  |  | $ | 5,745 |  |  | $ | — |  |  | $ | — |  |  | $ | 130,125 |

All other schedules are omitted because they are not applicable, or because the information required is included in the consolidated financial statements and notes thereto.
5
3

##### Table of Contents

3. Exhibits

The following exhibits are referenced or included in this Annual Report on Form 10-K.

Exhibit Number |  | Description
2.1 |  | Asset Purchase Agreement, dated December 1, 2022, by and between Ibeo Automotive Systems GmbH and MicroVision GmbH(14)
2.2 |  | Amendment Agreement, dated January 31, 2023, to the Asset Purchase Agreement, dated December 1, 2022, by and between Ibeo Automotive Systems GmbH and MicroVision GmbH(14)
3.1 |  | Amended and Restated Certificate of Incorporation of MicroVision, Inc., as amended.(2)
3.2 |  | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc.(4)
3.3 |  | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc. dated June 7, 2018.(6)
3.4 |  | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc. dated October 8, 2020.(8)
3.5 |  | Bylaws of MicroVision, Inc. (5)
4.1 |  | Form of Specimen Stock Certificate for Common Stock.(1)
4.2 |  | Description of Common Stock (9).
10.1 |  | 2022 MicroVision, Inc. Incentive Plan.(13)*
10.2 |  | Third Amendment to Lease Agreement between BRE WA Office Owner, LLC and MicroVision, Inc., dated July 25, 2017.(7)
10.3 |  | Change of Control Severance Plan.(3)*
10.4 |  | Employment Agreement between MicroVision, Inc. and Sumit Sharma dated April 8, 2021. (11)
10.5 |  | At-the-Market Issuance Sales Agreement, dated June 21, 2021, by and between the Company and Craig-Hallum Capital Group LLC(10)
10.6 |  | Lease Agreement between Redmond East Office Park LLC and MicroVision, Inc. dated September 24, 2021 (covering approximately 16,681 square feet). (12)
10.7 |  | Lease Agreement between Redmond East Office Park LLC and MicroVision, Inc. dated September 24, 2021 (covering approximately 36,062 square feet). (12)
10.8 |  | Form of Performance-Based Restricted Stock Unit Agreement(13)*
10.9 |  | Form of Restricted Stock Unit Agreement*
23.1 |  | Consent of Independent Registered Public Accounting Firm – Moss Adams LLP.
31.1 |  | Principal Executive Officer Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Principal Financial Officer Certification pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 |  | Principal Executive Officer Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) and Section 1350, Chapter 63 of Title 18, United States Code (18 U.S.C. 1350), as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
32.2 |  | Principal Financial Officer Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) and Section 1350, Chapter 63 of Title 18, United States Code (18 U.S.C. 1350), as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

54

##### Table of Contents

Exhibit Number |  | Description
101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH |  | Inline XBRL Taxonomy Extension Schema.
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

(1) | Incorporated by reference to the Company’s Post-Effective Amendment to Form S-3 Registration Statement, Registration No. 333-102244.

(2) | Incorporated by reference to the Company’s Form 10-Q for the quarterly period ended September 30, 2009.

(3) | Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2011.

(4) | Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 17, 2012.

(5) | Incorporated by reference to the Company’s Current Report on Form 8-K filed on November 27, 2013.

(6) | Incorporated by reference to the Company’s Amendment No. 2 to Form S-1 Registration Statement, Registration No. 333-222857.

(7) | Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2017.

(8) | Incorporated by reference to the Company’s Form 10-Q for the quarterly period ended September 30, 2020.

(9) | Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2020.

(10) | Incorporated by reference to the Company’s Current Report on Form 8-K filed on June 21, 2021.

(11) | Incorporated by reference to the Company’s Form 10-Q for the quarterly period ended June 30, 2021.

(12) | Incorporated by reference to the Company’s Form 10-Q for the quarterly period ended September 30, 2021.

(13) | Incorporated by reference to the Company’s Form S-8 filed on June 8, 2022.

(14) | Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 3, 2023.

* | Management contracts and compensatory plans and arrangements required to be filed as exhibits pursuant to Item 15(b) of this Annual Report on Form 10-K.

ITEM 16. | FORM 10-K SUMMARY

None.

55

##### Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |  |  |  | MicroVision, Inc.
Date: March 1, 2023 |  |  |  | By |  | /s/ Sumit Sharma
|  |  |  |  |  | Sumit Sharma Chief Executive Officer and Director

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sumit Sharma and Anubhav Verma, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the following capacities on March 1, 2023.

Signature |  | Title
/s/ Sumit Sharma Sumit Sharma |  | Chief Executive Officer and Director (Principal Executive Officer)
/s/ Anubhav Verma Anubhav Verma |  | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
/s/ Simon Biddiscombe Simon Biddiscombe |  | Director
/s/ Robert P. Carlile Robert P. Carlile |  | Director
/s/ Judy Curran Judy Curran |  | Director
/s/ Jeffrey Herbst Jeffrey Herbst |  | Director
/s/ Seval Oz Seval Oz |  | Director
Mark Spitzer |  | Director
/s/ Brian V. Turner Brian V. Turner |  | Director

56